

W.O. 94/23643 A1  
OCT 1994

LECTUAL PROPERTY ORGANIZATION  
International Bureau



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)


(51) International Patent Classification 5: A61B 5/00	(11) International Publication Number: WO 94/23643 A1 (43) International Publication Date: 27 October 1994 (27.10.94)
(21) International Application Number: PCT/US93/03427 (22) International Filing Date: 12 April 1993 (12.04.93)	(81) Designated States: AU, BG, CA, FI, HU, JP, KR, NO, NZ, PL, RU, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).
(71) Applicant: NONINVASIVE MEDICAL TECHNOLOGY CORPORATION (US/US); Suite 8, 333 2nd Street, Ogden, UT 84404 (US).	Published With international search report. With amended claims and statement.
(72) Inventors: STEUER, Robert, R.; 4157 North 900 West, Pleasant View, UT 84414 (US). HARRIS, David, B.; 1255 Valley Drive, No. 6, Ogden, UT 84401 (US).	
(74) Agents: BURNINGHAM, Kent, S. et al.; Workman, Nydegger & Jensen, 60 East South Temple #1000, Salt Lake City, UT 84111 (US).	

(54) Title: SYSTEM AND METHOD FOR NONINVASIVE HEMATOCRIT MONITORING

(57) Abstract

A system for determining the hematocrit transcutaneously and noninvasively. Disclosed are a finger clip assembly (6) and an earlobe clip assembly (10), each including at least a pair of emitters (1, 2) and a photodiode (3) in appropriate alignment to enable operation in either a transmission mode or a reflectance mode. At least two, and preferably three, predetermined wavelengths of light are passed onto or through body tissues such as the finger (7), earlobe (11), or scalp, etc. and the extinction of each wavelength is detected. Mathematical manipulation of the detected values

compensates for the effects of body tissue and fluid and determines the hematocrit value. If a fourth wavelength of light is used which is extinguished substantially differently by oxyhemoglobin and reduced hemoglobin and which is not substantially extinguished by plasma, then the blood oxygen saturation value, is determinable independently of the hematocrit value. It is also within the scope of the present invention to detect and analyze multiple wavelengths using a logarithmic DC analysis technique. In this embodiment, a pulse wave is not required. Hence, this embodiment may be utilized in states of low blood pressure or low blood flow.



**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	GB	United Kingdom	MR	Mauritania
AU	Australia	GE	Georgia	MW	Malawi
BB	Barbados	GN	Guinea	NE	Niger
BE	Belgium	GR	Greece	NL	Netherlands
BF	Burkina Faso	HU	Hungary	NO	Norway
BG	Bulgaria	IE	Ireland	NZ	New Zealand
BJ	Benin	IT	Italy	PL	Poland
BR	Brazil	JP	Japan	PT	Portugal
BY	Belarus	KE	Kenya	RO	Romania
CA	Canada	KG	Kyrgyzstan	RU	Russian Federation
CF	Central African Republic	KP	Democratic People's Republic of Korea	SD	Sudan
CG	Congo	KR	Republic of Korea	SE	Sweden
CH	Switzerland	KZ	Kazakhstan	SI	Slovenia
CI	Côte d'Ivoire	LI	Liechtenstein	SK	Slovakia
CM	Cameroon	LK	Sri Lanka	SN	Senegal
CN	China	LU	Luxembourg	TD	Chad
CS	Czechoslovakia	LV	Latvia	TG	Togo
CZ	Czech Republic	MC	Monaco	TJ	Tajikistan
DE	Germany	MD	Republic of Moldova	TT	Trinidad and Tobago
DK	Denmark	MG	Madagascar	UA	Ukraine
ES	Spain	ML	Mali	US	United States of America
FI	Finland	MN	Mongolia	UZ	Uzbekistan
FR	France			VN	Viet Nam
GA	Gabon				

-1-

5

SYSTEM AND METHOD FOR NONINVASIVE HEMATOCRIT MONITORINGBACKGROUND10 1. The Field of the Invention.

This invention relates to systems and methods for noninvasively measuring one or more biologic constituent values. More particularly, the present invention relates to noninvasive spectrophotometric systems and methods for  
15 quantitatively and continuously monitoring the hematocrit and other blood parameters of a subject.

2. The Prior Art.

Modern medical practice utilizes a number of procedures and indicators to assess a patient's condition.  
20 One of these indicators is the patient's hematocrit. Hematocrit (often abbreviated as Hct) is the volume, expressed as a percentage, of the patient's blood which is occupied by red corpuscles (commonly referred to as red blood cells).

25 Human blood consists principally of liquid plasma (which is comprised of over 90% water with more than 100 other constituents such as proteins, lipids, salts, etc.) and three different corpuscles. The three corpuscles found in blood are red corpuscles, white corpuscles, and  
30 platelets.

The chief function of red corpuscles is to carry oxygen from the lungs to the body tissues and carbon dioxide from the tissues to the lungs. This critical life supporting function is made possible by hemoglobin which is  
35 the principal active constituent of red corpuscles. In the lungs, hemoglobin rapidly absorbs oxygen to form oxyhemoglobin which gives it a bright scarlet color. As the red corpuscles travel to the tissues, the oxyhemoglobin

-2-

releases oxygen, i.e., is reduced, and the hemoglobin turns a dark red color.

5       The oxygen transportation functions of the body rely essentially entirely on the presence of hemoglobin in the red corpuscles. Red corpuscles greatly outnumber other corpuscles being about 700 times greater than the number of white corpuscles in a healthy human subject.

10       Medical professionals routinely desire to know the hematocrit of a patient. In order to determine hematocrit using any of the techniques available to date, it is necessary to draw a sample of blood by puncturing a vein or invading a capillary. Then, using a widely accepted technique, the sample of blood is subjected to a high speed centrifuge treatment for several minutes (e.g., 7 or more  
15       minutes). The centrifuging process, if properly carried out, separates the corpuscles into a packed mass. The volume occupied by the packed corpuscles, expressed as a percentage of the total volume of the plasma/corpuscle combination, is taken as the hematocrit.

20       It will be appreciated that the centrifuge process provides a hematocrit value which includes all corpuscles, not just red corpuscles. Nevertheless, the vastly greater numbers of red corpuscles in a healthy subject allows the hematocrit value obtained by the centrifuge process to be  
25       clinically usable in such healthy subjects. Nevertheless, in subjects with low hematocrit or dramatically high white corpuscle content, it may be desirable to diminish the effect of the non-red corpuscles when obtaining an hematocrit value.

30       There have been various techniques and devices introduced which have automated and increased the precision of obtaining a hematocrit value. Nevertheless, all the previously available techniques have one or more drawbacks.

35       Specifically, the previously available techniques all require that a sample of blood be withdrawn from the

-3-

patient for in vitro analysis. Any invasion of the subject to obtain blood is accompanied by the problems of inconvenience, stress, and discomfort imposed upon the subject and also the risks which are always present when the body is invaded. Drawing blood also creates certain contamination risks to the paramedical professional. Moreover, even in a setting where obtaining a blood sample does not impose any additional problems, e.g., during surgery, the previously available techniques require a delay between the time that the sample is drawn and the hematocrit value is obtained. Still further, none of the previously available techniques allow continuous monitoring of a subject's hematocrit, as might be desirable during some surgical procedures or intensive care treatment, but require the periodic withdrawal and processing of blood samples.

In view of the drawbacks inherent in the available art dealing with invasive hematocrit determinations, it would be an advance in the art to noninvasively and quantitatively determine a subject's hematocrit value. It would also be an advance in the art to provide a system and method for noninvasive hematocrit monitoring which can be applied to a plurality of body parts and which utilizes electromagnetic emissions as an hematocrit information carrier. It would be another advance in the art to provide a system and method which can provide both immediate and continuous hematocrit information for a subject. It would be yet another advance to provide repeatable and reliable systems for noninvasive monitoring of a subject's hematocrit. It would be still another advance in the art to noninvasively and accurately determine a subject's blood oxygen saturation while accounting for the patient's low or varying hematocrit and/or under conditions of low perfusion.

BRIEF SUMMARY AND OBJECTS OF THE INVENTION

The present invention is directed to apparatus and methods for determining biologic constituent values, such as the hematocrit value, transcutaneously and noninvasively. This is achieved by passing at least two wavelengths of light onto or through body tissues such as the finger, earlobe, or scalp, etc. and then compensating for the effects body tissue and fluid effects. As used herein, the term biologic constituent includes proteins, red cells, metabolites, drugs, cytochromes, hormones, etc.

In one embodiment within the scope of the present invention, the wavelengths of light are selected to be near or at the isobestic points of reduced hemoglobin and oxyhemoglobin to eliminate the effects of variable blood oxygenation. At an isobestic wavelength, the extinction coefficient,  $\epsilon$ , is the same for both reduced and oxygenated hemoglobin. Thus, at isobestic wavelengths, the amount of light absorption is independent of the amount of oxygenated or reduced hemoglobin in the red cells.

Means are provided for delivering and detecting those wavelengths of light and for analyzing the light intensities. The sensing and radiation emitting elements are preferably spatially arranged to allow ease of use and to be accessible to a patient's exterior body parts. The configuration of the sensing and emitting elements is important to give optimum repeatability of the signals and data derived therefrom.

Memory and calculation means are included which are capable of storing, manipulating, and displaying the detected signals in a variety of ways. For instance, the continuous pulse wave contour, the pulse rate value, the hematocrit value and the continuous analog hematocrit curve in real time, the hematocrit-independent oxygen saturation value, and the oxygen content value of the blood, all as

-5-

digital values or as continuous analog curves in real time are capable of being displayed.

5 An important advantage of monitoring and analyzing each individual pulsatile signal is that averaging algorithms may be performed for identifying and rejecting erroneous data. In addition, such techniques also improve repeatability.

10 Another significant advantage of the present invention is the capability of monitoring multiple wavelengths (including nonisobestic wavelengths) for the simultaneous real time computation and display of the hematocrit-independent oxygen saturation value. Techniques in prior art oximetry have all suffered inaccuracies due to hematocrit sensitivities.

15 Rather than apply AC-DC cancellation techniques only, it is also within the scope of the present invention to detect and analyze multiple wavelengths using a logarithmic DC analysis technique. In this embodiment, a pulse wave is not required. Hence, this embodiment may be utilized in states of low blood pressure or low blood flow.

#### BRIEF DESCRIPTION OF THE DRAWINGS

Figure 1 is a perspective view of a first presently preferred embodiment of the present invention.

25 Figure 1A is an enlarged cross sectional view of the body part (finger) and system components represented in Figure 1 used in a transmission mode.

Figure 1B is an enlarged cross sectional view of the body part (finger) and associated system components represented in Figure 1 used in a reflective mode.

30 Figure 2 is a chart showing the optical absorption coefficients of oxyhemoglobin ( $\text{HbO}_2$ ), reduced hemoglobin (Hb), and water ( $\text{H}_2\text{O}$ ) versus wavelength.

-6-

Figure 3 is a chart showing the relationship between the extinction coefficient of light at three different wavelengths versus hematocrit for whole blood.

5 Figure 4 is a chart showing the relationship between the ratio of the extinction coefficients of two rays having differing wavelengths versus hematocrit.

10 Figures 5A-5E provide a flow chart showing the steps carried out during one presently preferred method of the present invention using the pulsatile component of the subject's blood flow to provide accurate hematocrit and blood oxygen saturation values.

15 Figure 6 is a perspective view of a second presently preferred system of the present invention which is applied to the ear and includes structures to squeeze out the blood to blanch the ear tissues.

Figure 6A is an enlarged cross sectional view of the ear and system components represented in Figure 6.

20 Figure 7 provides a detailed schematic diagram of the low level sensor circuitry included in the presently preferred system of the present invention.

Figures 8A-8C provide a detailed schematic diagram digital section circuitry included in the presently preferred system of the present invention.

25 Figures 9A-9D provide a detailed schematic diagram of the analog section circuitry included in the presently preferred system of the present invention.

Figures 10A-10C provide a detailed schematic diagram of the power supply and input/output (I/O) section included in the presently preferred system of the present invention.

30 Figure 11 is a graph showing variation in oxygen saturation as a function of hematocrit.

Figure 12 is a graph of  $\epsilon_{b805}/\epsilon_{b970}$  versus Hematocrit.

35 Figures 13A-13B are graphs of  $\epsilon$  versus Hematocrit at two non-preferred wavelengths and  $\epsilon_1/\epsilon_2$  versus Hematocrit at those non-preferred wavelengths.

-7-

Figures 14A-14B are graphs of  $\epsilon$  versus Hematocrit at two non-preferred wavelengths and  $\epsilon_1/\epsilon_2$  versus Hematocrit at those non-preferred wavelengths.

Figure 15 illustrate vertical emitter alignment and the resulting non-identical  $\Delta X_b$  regions.

Figure 16 illustrates horizontal emitter alignment.

#### DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

The present invention is directed to apparatus and methods for determining biologic constituent values, such as the hematocrit value, transcutaneously and noninvasively. This is achieved by passing at least two wavelengths of light onto or through body tissues such as the finger, earlobe, or scalp, etc., and then compensating for the effects of body tissue and fluid by modifying the Beer-Lambert Law. The principles within the scope of the present invention may also be utilized to provide a hematocrit-independent oxygen saturation and oxygen content measurements as well as noninvasive measurement of blood constituents such as glucose, cholesterol, bilirubin, creatinine, etc.

Although the present invention will describe in great detail the transillumination of various body parts, it will be appreciated that reflectance spectrophotometry may alternatively be employed where transillumination is difficult to accomplish. As used herein, the term "body part" is intended to include skin, earlobe, finger, lip, forehead, etc. Because the principles within the scope of the present invention can be adapted by those skilled in the art for in vitro measurement of hematocrit and other blood constituents, the term "body part" is also intended to include various in vitro blood containers such as tubes and cuvettes.

### 1. Spectrophotometric Methods

Spectrophotometric methods have been described in the prior art which monitor various metabolites in body fluids. Radiation, typically in the visible or near infrared region, is directed onto an exterior body part for transcutaneous penetration of the radiation. The radiation is then monitored reflectively or transmissively by a photodetector or similar sensor. Radiation spectra are chosen at wavelengths where the metabolite or compound sought for either absorbs highly or poorly. Some examples of such spectrophotometric methods are described in U.S. Patent No. 4,653,498 for pulse oximetry, U.S. Patent No. 4,655,225 for blood glucose monitoring, and more recently U.S. Patent No. 4,805,623 for monitoring various blood metabolites (glucose, cholesterol, etc.).

A theoretical basis for the spectrophotometric techniques is the Beer-Lambert Law:

$$I = I_0 e^{-\epsilon X d} \quad (1)$$

Equation (1) may also be written:

$$\ln(I/I_0) = -\epsilon X d \quad (1a)$$

wherein  $I_0$  is the incident intensity of the source radiation,  $I$  is the transmitted intensity of the source through the sample,  $\epsilon$  is the extinction coefficient of the sought for component,  $X$  is the concentration of the sample component in the tissue itself, and  $d$  is the optical path length (distance).

The Beer-Lambert Law (1) permits in vitro solute concentration determinations. However, quantitative measurements have not been possible in the body since the scattering of the incident photons passing into and through the integument and subdermal regions is extensive and

-9-

highly variable. This scattering spoils the Beer-Lambert Law by adding a variable loss of radiation to the measurement and also extends the path length of the incident photons by an unknown amount as well.

5           Even though optical pulse rate monitors, plethysmographs, and pulse oximeters are known, their development has been accelerated by techniques which allow for cancellation of the optical scattering effects to a large extent. This development began with U.S. Patent  
10       No. 2,706,927 and was further refined by Yoshiya, et. al. (Med. and Biol. Eng. and Computing, 1980 Vol. 18, Pages. 27-32), Koneshi in U.S. Patent No. 3,998,550, and Hamaguri in U.S. No. Patent 4,266,554, which utilized a technique of analyzing the resultant opto-electronic signal  
15       by dividing it into its AC and DC components. The AC and DC components are manipulated with logarithmic amplifiers in such a way as to eliminate the above-mentioned transdermal optical effects (the variable amount of radiation loss due to scattering in the tissue and the  
20       unknown and variable amounts of optical path length increase).

Until now, the AC-DC cancellation techniques have not been successfully adapted for the measurement of hematocrit or hematocrit-independent blood oxygen saturation.

25       2.   Noninvasive Differential-Ratiometric Spectrophotometry

It is assumed that incident radiation passing onto or into a living tissue will pass through a combination of blood, tissue, and interstitial fluid compartments. The

-10-

light attenuated by such a living tissue can be expressed by the modified Beer-Lambert equation:

$$I = I_0 e^{-(\epsilon_b(X_a+X_v)+\epsilon_t X_t+\epsilon_i X_i)d+G} \quad (2)$$

5

Equation (2) may also be written

$$\ln(I/I_0) = -(\epsilon_b(X_a+X_v)+\epsilon_t X_t+\epsilon_i X_i)d+G \quad (2a)$$

10 Where  $\epsilon_b$ ,  $\epsilon_t$ , and  $\epsilon_i$  represent the extinction coefficient in the blood, tissue, and interstitial fluid compartments, respectively;  $X_a$  and  $X_v$  represent the arterial and venous blood concentration ( $X_b=X_a+X_v$ ),  $X_t$  represents the concentration of the tissue absorbers, and  $X_i$  represents the  
15 relative concentration of water and dissolved components in the interstitial fluid compartment;  $d$  represents the intrasensor spacing; and  $G$  is a constant of the geometric configuration.

As the blood layer pulsates, the concentration terms  
20 change. The term  $d$  can be fixed by the geometric configuration of the device. Taking the partial derivatives of equation (2) with respect to time and dividing by equation (2) gives:

$$-\frac{\partial I/\partial t}{I} = (\epsilon_b(\partial X_a/\partial t + \partial X_v/\partial t) + \epsilon_t \partial X_t/\partial t + \epsilon_i \partial X_i/\partial t)d + \partial G/\partial t \quad (3)$$

25 which can be simplified at each compartment and wavelength by letting  $X' = \partial X/\partial t$ , and  $G' = \partial G/\partial t$ , and  $V'_\lambda = -\left(\frac{\partial I/\partial t}{I}\right)_\lambda$  to give

$$V'_\lambda = (\epsilon_b(X'_a + X'_v) + \epsilon_t X'_t + \epsilon_i X'_i)d + G' \quad (4)$$

Assuming that  $X_t$  and  $G$  do not vary significantly over the pulse time interval, then  $G' = 0$  and  $X'_t = 0$ , and equation (4)  
30 can be simplified to

-11-

$$V'_\lambda = (\epsilon_b(X'_a + X'_v) + \epsilon_i X'_i) d \quad (5)$$

Examining the transport between  $X_a$  and  $X_v$ , we can form a proportionality constant  $K_v$  such that  $X'_v = -K_v X'_a$ , representing the reactionary nature of the venous component, and further reduce the above equation to

$$V'_\lambda = (\epsilon_b(1 - K_v)X'_a + \epsilon_i X'_i) d \quad (6)$$

Since  $X'_a$  and  $X'_i$  are not wavelength ( $\lambda$ ) dependent,  $V'_\lambda$  values at different wavelengths can be differentially subtracted to produce a hematocrit independent term which contains only  $\epsilon_i X'_i$  information. Although the term  $V'_{805}/V'_{1310}$  provides useful information regarding relative changes in hematocrit, it should be recognized that the simple  $V'_{805}/V'_{1310}$  ratio is not sufficiently accurate for hematocrit value determination unless the  $\epsilon_i X'_i$  term is known or eliminated. For example, the  $\epsilon_i X'_{i805}$  term can be neglected since  $\epsilon_{i805}$  is extremely small, whereas the  $\epsilon_i X'_{i1310}$  term is about 25%-50% of the  $\epsilon_{b1310}$  value of blood itself and cannot, therefore, be neglected without affecting accuracy.

Figures 3 and 12 suggest that a linear combination of  $V'_\lambda$  at  $\lambda=805$  nm and  $\lambda=970$  nm will have a near constant value for a range of Hct values. Since the extinction coefficients  $\epsilon_{i805}$  and  $\epsilon_{i970}$  are well known, or can be empirically determined, a precise proportionality constant  $R_1$  can be found to produce

$$\epsilon_{i970} X'_i = V'_{970} - R_1 V'_{805} \quad (7)$$

25

This correction term can now be applied with a second proportionality constant  $R_2$  (where  $R_2$  is approximately equal

-12-

to  $\epsilon_{i1310}/\epsilon_{i970}$  to the  $V'_{1310}$  term to exactly remove its  $\epsilon_{i1310}X'_i$  sensitivity, hence:

$$\epsilon_{b1310}(1-K_v)X'_a = V'_{1310} - R_2(V'_{970} - R_1V'_{805}) \quad (8)$$

5 This corrected term can now be used ratiometrically with  $V'_{805}$  to remove the  $(1-K_v)X'_a$  and leave the pure extinction coefficient ratio represented by Equation (9) below and shown graphically in Figure 4.

$$\frac{\epsilon_{b805}}{\epsilon_{b1310}} = \frac{V'_{805}}{V'_{1310} - R_2(V'_{970} - R_1V'_{805})} \quad (9)$$

10 It should be noticed that the following assumptions and requirements are essential in hematocrit determinations (but in the case of pulse oximetry these requirements may not be of the same degree of significance).

15 A. Even though wavelengths  $\lambda=805$  nm and  $\lambda=1310$  nm are near isobestic, the actual function of  $\epsilon$  versus Hematocrit at each given wavelength must hold hematocrit information that is different in curvature, or offset, or linearity, or sign from the other. See Figure 3. If the functions  $\epsilon_1$  versus hematocrit are not sufficiently different, then the ratio  $\epsilon_{b\lambda1}/\epsilon_{b\lambda2}$  will not hold hematocrit information. See Figures 13A and 13B and Figures 14A and 14B. Even though the foregoing discussion refers to the isobestic wavelengths of  $\lambda=805$  nm and  $\lambda=1310$  nm, it will be appreciated that other isobestic wavelengths, such as  $\lambda=570$  nm,  $\lambda=589$  nm, and  $\lambda=1550$  nm, may also be utilized.

25 B. Further, the wavelengths should be selected close enough to one another such that the optical path lengths,  $d$ , are approximately the same. Longer wavelengths are preferred since they exhibit less sensitivity to scattering,  $s$ :

-13-

$$s \propto \frac{1}{\lambda^2} \quad (10)$$

C. The geometric or spatial relationship of the emitters and sensors is important. For instance, if vertically aligned emitters are used in an earlobe-measuring device, then the top-most emitter may illuminate a different amount of blood filled tissue than the lower emitter. If only one sensor is used, then there will be a disparity between  $X'_b$  at each wavelength. See Figure 15, wherein  $X_{b1} > X_{b2} > X_{b3}$ . Furthermore, the sensor-emitter spatial separation distance is very important because the pressure applied to the tissue between the sensor and emitters affects the arteriolar and capillary vessel compliance. This changes the  $X'$  as the pressure (or distance) changes. This change in  $X'$  then modulates the  $V'_1$  function. Therefore, the sensor-emitter separation distance must be such that the pressure applied to the earlobe, fingertip, or other body member, does not affect the  $V'_1$  function. This sensor separation distance is empirically determined and should generate less than 40 mm Hg applied transmural pressure.

A horizontal alignment (Figure 15) of the emitters with respect to the single sensor can be arranged so that the emitters and sensors illuminate and detect identical regions of  $\partial X_{11}$  and  $\partial X_{12}$ . It is important to note that the term  $d$ , the sensor-emitter separation, will be different between  $\lambda_1$  and  $\lambda_2$  by the cosine of the angle between the sensor and emitter. Therefore, if any misalignment from normal occurs, the term  $d$  will not cancel to obtain equation (9).

The preferred arrangement is wherein all the emitters (660, 805, 950, and 1310 nm) are located on the same substrate. This is preferred because the emitters will then illuminate essentially the same  $X_b$  region.

-14-

D. In the case of reflectance spectrophotometry, an aperture for the sensor and each emitter is required. See Figure 1B. Also, a sensor-emitter separation is required so that the reflectance of the first layer of tissue,  $R_t$ , (a non-blood layer of epithelium) does not further exaggerate a multiple scattering effect, i.e. the total reflectance,  $R$ , measured would contain spurious information of the epithelial layers' reflectance as well, where:

$$R = R_t + \frac{T_t^2 \cdot R_b}{(1 - R_b \cdot R_t)} \quad (11)$$

where  $R$  is the total reflectance;  $R_t$  is the reflectance due to the first tissue-epithelial layer,  $R_b$  is the reflectance due to the blood layer, and  $T_t$  is the transmission through the first tissue layer.

The reflectance equations describing  $R_t$  or  $R_b$  must now sum all of the backscattered light that the sensor detects, i.e.,:

$$R_b = \iiint (\text{source function}) \cdot (\text{scattering function}) \quad (12)$$

While equation (9) describes the theory of the noninvasive hematocrit device, the four assumptions (A-D) are important to the repeatability and accurate functioning of the hematocrit device.

Assuming items A through D are dealt with appropriately, then (9) becomes:

$$\frac{\epsilon_{b\lambda 1}}{\epsilon_{b\lambda 2}} = \frac{(S_1 + k_1)}{(S_2 + k_2)} \quad (13)$$

-15-

where  $s$  is a scattering constant and  $k$  is an absorption constant, and where in whole blood:

$$s = \sigma_s \text{Hct}(1-\text{Hct}) \quad (14)$$

5

$$k = \sigma_a \text{Hct} \text{ (at isobestic wavelengths)} \quad (15)$$

where  $\sigma_s$  is the scattering cross section and  $\sigma_a$  is the absorption cross section.

10 From the foregoing,  $\epsilon$ , the extinction coefficient, is not a simple function of the absorption coefficient,  $k$ , normally determined in pure solutions. Rather, it contains a diffusion or scattering term,  $s$ , which must be accounted for in a non-pure solution media such as whole blood and  
15 tissue.

Finally, substituting (14) and (15) into (13):

$$\frac{\epsilon_{\lambda 1}}{\epsilon_{\lambda 2}} = \frac{\sigma_{s1}(1-\text{Hct}) + \sigma_{a1}}{\sigma_{s2}(1-\text{Hct}) + \sigma_{a2}} \quad (16)$$

Therefore, the ratio  $\epsilon_{\lambda 1}/\epsilon_{\lambda 2}$  is a function of hematocrit. From Figure 4, a look up table or polynomial  
20 curve fit equation may be obtained and utilized in the final displayed hematocrit results. Knowing the actual hematocrit value, it is straightforward to see (Figure 2) that a wavelength at 660 nanometers can be selected to obtain an  $\epsilon$  ratio wherein the hematocrit-independent oxygen  
25 saturation value is derived. For example, equation (16) would become:

$$\frac{\epsilon_{b660}}{\epsilon_{b805}} = \frac{\sigma_{s660}(1-\text{Hct}) + \sigma_{a660} + S_a O_2 (\sigma_{ao660} - \sigma_{ar660})}{\sigma_{s805}(1-\text{Hct}) + \sigma_{a805} + S_a O_2 (\sigma_{ao805} - \sigma_{ar805})} \quad (17)$$

Equation (17) shows both the hematocrit and oxygen saturation dependence on each other.

-16-

Figure 11 graphically demonstrates the need for a hematocrit-independent blood saturation device. As either the hematocrit value or percent oxygen saturation decreases, the percent saturation error becomes unacceptable for clinical usage. For example, it is not uncommon to see patients with a low hematocrit (about 20%) who have respiratory embarrassment (low oxygen saturation) as well. Hence, the clinician simply requires more accurate oxygen saturation values.

Knowing the hematocrit and oxygen saturation values, the computation of the Oxygen Content is trivial and may be displayed directly (a value heretofore unavailable to the clinician as a continuous, real-time, noninvasive result):

$$[\text{Oxygen Content}] = \text{Hct} \cdot S_a\text{O}_2 \cdot K \quad (18)$$

where K is an empirically determined constant.

Referring to the equations (16) and (9) a decision must be made by the computer as to the suitability of utilizing the Taylor expansion approximation to the logarithm. This algorithm is maintained in the software as a qualifying decision for the averaging and readout algorithms. The Taylor approximation is only valid for small  $\partial I / \partial t$  values.

### 3. Nonpulsatile Applications

#### a. Valsalva's Maneuver to Simulate Pulsatile Case

It is interesting to see the similarities between this AC pulsatile derivation and an analogous DC technique. By taking the logarithm of two intensity ratios, values of  $\epsilon_b$  and  $\epsilon_i$  can be obtained from the modified Beer-Lambert equation (equation (2a)). These same extinction coefficients can be manipulated by the identical proportionality constants  $R_1$  and  $R_2$  found previously to exactly eliminate  $\epsilon_{i1310} X_i$  and yield

-17-

$$\frac{\epsilon_{b805}}{\epsilon_{b1310}} = \frac{U_{805}}{U_{1310} - R_2(U_{970} - R_1 U_{805})} \quad (19)$$

Where the term  $U_1 = \ln\left(\frac{I_2}{I_1}\right)$  represents the logarithm of intensity ratios at  $X_b$  values of  $X_1$  and  $X_2$ .

It should also be noted that the two derivations (AC and DC) fold into one another through the power series expansion of the  $\ln(1+Z)$  function:

$$\ln(1+Z) = Z - \frac{Z^2}{2} + \frac{Z^3}{3} - \dots \quad (20)$$

When the value  $\Delta I = I_2 - I_1$ , it can be seen that

$$\ln\left(\frac{I_2}{I_1}\right) = \ln\left(\frac{\Delta I + I_1}{I_1}\right) = \ln\left(1 + \frac{\Delta I}{I_1}\right) = \frac{\Delta I}{I_1} + \text{High Order Terms} \quad (21)$$

which means that for small changes in  $X_b$ , the AC (partial derivative) and DC (logarithmic) derivations are similar and can each be precisely compensated through this differential-ratiometric technique to provide an noninvasive  $\epsilon_{b805}/\epsilon_{b1310}$  ratio which is independent of both the constant and time-varying tissue and interstitial fluid terms.

One currently preferred method of obtaining the two intensity ratios is to have the patient perform Valsalva's maneuver. Valsalva's maneuver is an attempt to forcibly exhale with the glottis, nose, and mouth closed. This maneuver increases intrathoracic pressure, slows the pulse, decreases return of blood to the heart, and increases venous pressure. Obtaining intensity measurements before and during Valsalva's maneuver provide sufficiently different intensity ratios to utilize equation (19). Even a deep breath can be enough to obtain sufficiently different intensity ratios.

-18-

b. Stepper Motor Technique

Another technique to simulate pulsatile blood flow and to eliminate the skin's optical scattering effects, while at the same time preserving the blood-borne hematocrit and oxygen saturation information, is described below. By utilizing a stepper motor 9 in the earlobe clip assembly 10 on an earlobe 11 of a patient such as that illustrated in Figures 6, 6A, 15, and 16, one can produce a variation of  $X_b$  sufficient to utilize equation 19. The stepper motor 9 could even produce a bloodless ( $X_b=0$ ) state, if required. However, equation 19 shows that only a difference between  $X_{b1}$  and  $X_{b2}$  is needed.

The major advantage of this technique is that under clinical conditions of poor blood flow, poor blood pressure, or peripheral vascular disease, where pulse wave forms are of poor quality for the  $(\partial I/\partial t)/I$  technique, this DC stepper motor technique could be utilized.

c. Oxygen Saturation Determination

The above techniques describe conditions and equations wherein isobestic wavelengths are chosen such that the hematocrit value obtained has no interference from oxygen saturation, hence an independently determined hematocrit value.

One, however, may choose  $\lambda_2$  (the reference wavelength) in equation (13) at 1550 nm as well. In the radiation region 900 to 2000 nm the blood absorption coefficients depend on hematocrit and water, whereas at 805 nm the blood absorption coefficient only depends on hematocrit. Therefore, utilizing in combination, wavelengths of 660, 805, and 1550 will also give a technique to determine hematocrit ( $\epsilon_{805}/\epsilon_{1550}$ ) and oxygen saturation ( $\epsilon_{660}/\epsilon_{805}$ ).

These 3 wavelengths are particularly important since 660, 805, and 1550 nm (or 1310 nm) are readily available LEDs, such as, respectively, MLED76-Motorola, HLP30RGB-Hitachi, and ETX1550-EPITAXX (or NDL5300-NEC), with the

-19-

benefits of low cost and low optical power (reducing any question of possible eye damage).

The manufacturing of a multi-chip LED emitter becomes reasonable, cost-wise, and provides increased accuracy since the LED sources have practically no separation  
5 distances and appear as a single point source.

This invention may be applied to the determination of other components (included, but not limited to, glucose, or cholesterol) in any range of the electromagnetic spectrum  
10 in which spectrophotometric techniques can be utilized.

#### 4. Currently Preferred Apparatus

An earlobe clip assembly 10 as in Figures 6, 6A, 15, and 16 (with or without the stepper motor 9 shown in Figure 6A) a finger clip assembly 6 used on a finger 7 as  
15 shown in Figures 1, 1A, and 1B are two currently preferred embodiments for practicing the present invention. The photodiodes 3 and emitters 1 and 2 in each are placed in accordance with appropriate alignment.

Consider first the sensor technology in the transmissive mode of operation. An earlobe or fingertip  
20 housing can be provided with discreet emitters and two photodiode chips (of different sensitivity ranges, 600-1000 nm and 1000-1700 nm ranges) placed on one substrate, such as a TO-5 can (Hamamatsu K1713-03). The emitters  
25 likewise can be two or more emitter chips (i.e.,  $\lambda$  = 805, 1310, 660, and 950 nm) placed on a common substrate and illuminated through a TO-39 can.

Finally, a single substrate multi-wavelength emitter and a multi-wavelength detector, assembled in one small  
30 physical housing for each, make alignment and detection sensitivity more repeatable, and hence more accurate.

The preferred emitter chips would have wavelengths, for hematocrit-only measurements, at 805 nm, 950 nm, and 1310 nm (or 805 nm, 950 nm, and 1550 nm). Although in  
35 theory, an emitter having a wavelength of 970 nanometers,

-20-

rather than 950 nm, would provide more accurate information, 970 nm emitters are not presently available commercially. These wavelengths are currently preferred because of the different curvature and baseline offset of the  $\epsilon$  versus Hematocrit at those wavelengths. See Figure 3. Hence, the hematocrit information will exist in the ratio  $\epsilon_{11}/\epsilon_{12}$ . See Figure 4.

Furthermore, the choice of 805 nm and 1310 nm (or 1550 nm) rather than 570 nm and 805 nm is because there is no water absorption in the 570 nm (or 589 nm) and 805 nm isobestic wavelengths. However, there is tremendous water absorption at 1310 nm and 1550 nm. Hence, the ratio of 570 nm to 805 nm, as a reference, would not yield hematocrit information because there would be no offset due to water in the plasma. See Figures 13A and 13B and Figures 14A and 14B.

If hematocrit-independent oxygen saturation is desired then the emitter chip wavelengths would be 660 nm, 805 nm, 950 nm, and 1310 nm (or 1550 nm) (the 660 nm is MLED76, Motorola or TOLD 9200, Toshiba). Likewise, the photodetector single substrate could house at least two chips, such as a Hamamatsu K1713-03.

It will be appreciated that those skilled in the art would be able to add other chips to the single substrate at wavelengths sensitive to other metabolites (glucose, cholesterol, etc.). The above mentioned emitter and detector connections can be seen in the analog schematic diagram illustrated in Figures 7 and 9B-9D.

The sensor technology in the reflectance mode must conform to two embodiment parameters. See Figure 1B. The diameter and thickness of the aperture 8 in which figure 7 is received in combination with the sensor-emitter separation distance are important to provide a detection region within the subdermis 12 at points a and b of Figure 1B, where the radiation impinges on blood-tissue

-21-

without the multiple scattering effects of the epithelial layer,  $R_t$ . The determination of optimum sensor 3 separation and aperture 8 sizes is done empirically from numerous fingers 8 with varying callous and fingernails 13. Minimum sensor separation and aperture diameters can be established wherein  $R_t$ , of equation (14) is eliminated.

Figures 7, 8A-8C, 9A-9D, and 10A-10B detail the electronics of one circuit suitable for use within the scope of the present invention. The memory and computation means (Figures 8A-8C) are connected via a "bus" structure between PROMS (U110,U111), microprocessor MC68HC000 (U106), static RAMS (U112,U113), and isolation buffers to the low-level analog circuitry (Figure 7). A crystal controlled oscillator circuit (U101A,B) is divided by 2 to provides a symmetric master clock to the microprocessor; this clock is further subdivided and used to provide clocking for the analog-to-digital converter (U208) and timer (U109). Strobe lines are generated through a decoder arrangement to drive each of the subsystems of the device and also control the isolation bus buffers (U201,U202).

Timer outputs are fed back into the microprocessor and encoded (U104) to produce interrupts at specific intervals for system functions. One timer is shared by subsystems which control the liquid crystal display means, the keyboard entry means, the audible indicator, and the cycling background system self-test. Another timer is dedicated exclusively to provide a high priority interrupt to the microprocessor; this interrupt drives software which controls the basic sensor sampling mechanism. An expansion connector (J101) is included to allow extended testing of the device or connection to external data-logging equipment such as a printer or computer interface.

The local bus isolates the sensitive analog circuitry from the main digital circuitry. This prevents spurious crosstalk from digital signals into the analog circuitry

-22-

and thereby reduces superimposed noise on the measured signals. It is on this local bus that the Digital-to-Analog Converters (DAC) and Analog-to-Digital Convertors (ADC) transmit and receive digital information while  
5 processing the low-level analog signals.

The Low Level Sensor electronic section, Figure 7, combines subsystems to both measure and modulate the current produced from each optical sensor. Since the pulsatile component of the optical energy transmitted  
10 through or reflected off of tissue comprises only a small part of the overall optical energy incident on the sensor, means are provided to "null out" in a carefully controlled and accurately known way the non-pulsatile component of the light-produced current in the sensing detector. The  
15 remaining signal can then be dc-amplified and filtered in a straightforward manner and presented to the ADC (U208) for conversion into a digital value representative of the relative AC pulsatile component. Furthermore, because the relationship between the nulling current and the average  
20 value of this AC component is known, the DC component can easily be calculated as a function of the sensing means' sensitivities and the electronic stages' gains. The functions determining these AC and DC values can (if necessary) be trimmed in software by calibration constants  
25 which are stored in EEPROM (U307) and retrieved each time the unit is powered on.

The current which modulates the optical sources (LEDs or Laser Diodes) is also controlled (U203) and precisely adjusted (U306) to optimize signal reception and detection.  
30 Through software control, the modulation current can be adjusted on a pulse-by-pulse basis to minimize noise-induced inaccuracies. Furthermore, by sampling the sensors with the modulation sources disabled appropriately, background noise (such as 60 Hz) can be rejected digitally  
35 as common-mode noise. Thus, by controlling the optical

-23-

source energy and modulating the nulling current in the photosensor circuitry, it is possible to effectively cancel the effects of ambient radiation levels and accurately measure both the static (DC) and time-varying (AC) components of transmitted or reflected light.

Interrupt-driven software algorithms acquire the sensor data, provide a real-time pulse wave contour, and determine pulse boundaries. Completed buffers (i.e. one entire pulse per buffer) of sensor data are then passed to the foreground software processes for computation. This involves the determination of the background-compensated AC pulsatile and DC static values of intensities for each wavelength. Through averaging and selective elimination of abnormal values, results are then calculated using equation (9) and displayed on the LCD. The modulating and nulling currents are (if necessary) also adjusted to utilize the electronic hardware efficiently and optimally.

#### 5. Summary

Although the foregoing discussion has related to noninvasive analysis of blood hematocrit information, it will be appreciated that the above-mentioned emitters, sensors, and circuitry may be adapted for invasive in vitro analysis of blood hematocrit values. The principles within the scope of the present invention which compensate for spatial, geometric, and tissue variations may be used to compensate for similar variations in an in vitro blood container. Such a device would allow hematocrit values to be determined rapidly and accurately.

Those skilled in the art will also appreciate that the methods within the scope of the present invention for determining blood hematocrit values may be adapted for determining non-hematocrit biologic constituent values such as glucose, cholesterol, etc. To determine biologic constituent information, the effects of competing blood, tissue, and interstitial fluid constituents must be

-24-

eliminated. It is believed that these effects may be eliminated by appropriate modification of the differential ratiometric techniques described above.

It is important to recognize that the present invention is not directed to determining the tissue hematocrit value. The tissue hematocrit value, in contrast with the blood hematocrit value, reflects the amount of red blood cells in a given volume of tissue (blood, interstitial fluids, fat, hair follicles, etc.). The present invention is capable of determining actual intravascular blood hematocrit and hemoglobin values.

From the foregoing, it will be appreciated that the present invention provides a system and method for noninvasively and quantitatively determining a subject's hematocrit or other blood constituent value. The present invention determines the hematocrit noninvasively by utilizing electromagnetic radiation as the transcutaneous information carrier. Importantly, the present invention may be used on various body parts to provide accurate quantitative hematocrit values.

It will also be appreciated that the present invention also provides a system and method which can provide immediate and continuous hematocrit information for a subject. The present invention further provides a system and method for noninvasively determining a subject's blood oxygen saturation ( $S_aO_2$ ) independent of the subject's hematocrit. In addition, the present invention provides a system and method for noninvasively determining a subject's hematocrit and/or blood oxygen saturation even under conditions of low blood perfusion.

The present invention may be embodied in other specific forms without departing from its spirit or essential characteristics. The described embodiments are to be considered in all respects only as illustrative and not restrictive. The scope of the invention is, therefore,

-25-

indicated by the appended claims rather than by the foregoing description. All changes which come within the meaning and range of equivalency of the claims are to be embraced within their scope.

5           What is claimed is:

-26-

1. A method for determining a desired biologic constituent concentration of the blood of a patient, the blood flowing in a pulsatile fashion in a body part of the patient or in an extracorporeal passageway in communication with the circulatory system of the patient so as to be subjectable to transcutaneous examination in the body part or to noninvasive examination in the extracorporeal passageway, the body part and the extracorporeal passageway defining a blood conduit and the method comprising the steps of:

(a) placing the blood conduit within a blood conduit receiving means with the blood flowing in the blood conduit;

(b) directing radiation into the flowing blood within the blood conduit using a radiation generation means situated within said blood conduit receiving means, said radiation defining a directed radiation comprising:

(i) a first quantity of a radiation at a first radiation wavelength which, when directed into the flowing blood within the blood conduit,

(A) has a first extinguishment value which varies with the desired biologic constituent concentration in the flowing blood and

(B) has a second extinguishment value which varies with the concentration of components other than the desired biologic constituent in the flowing blood, which second extinguishment value is at least ten times smaller than said first extinguishment value; and

(ii) a first quantity of a radiation at a second radiation wavelength, distinct from said

-27-

first wavelength, which, when directed into the flowing blood within the blood conduit,

5 (A) has a third extinguishment value which for varying concentrations in the flowing blood of the desired blood constituent is a non fixed multiple of said first extinguishment value and

10 (B) has a fourth extinguishment value which varies with the concentration of components other than the desired biologic constituent in the flowing blood, which fourth extinguishment value is at least ten times greater than said second extinguishment value;

15 (c) detecting the portion of said directed radiation which passes through both the blood conduit and the flowing blood therein using a radiation detection means situated within said blood conduit receiving means, said detected portion of said  
20 directed radiation comprising:

(i) a second quantity of a radiation at the first radiation wavelength, and

(ii) a second quantity of a radiation at the second radiation wavelength;

25 (d) operating exclusively on the second quantities of the radiations at the first and second radiation wavelengths to determine the desired biologic constituent concentration.

30 2. A method as defined in Claim 1, wherein the step of detecting the second quantity of the first radiation wavelength comprises the steps of:

(a) determining the intensity of the total first radiation wavelength;

35 (b) determining a first radiation wavelength pulsatile value representing the difference between

-28-

the maximum and the minimum intensity of the pulsatile component of the first radiation wavelength;

5 (c) determining the ratio between the first radiation wavelength pulsatile value and the intensity of the total first radiation wavelength over a period of time; and

10 (d) determining a first mean ratio value over a period of time of the ratio between the first radiation wavelength pulsatile component and the average intensity of the first radiation wavelength.

3. A method as defined in Claim 2, wherein the step of detecting the second quantity of the second radiation wavelength comprises the steps of:

15 (a) determining the intensity of the total second radiation wavelength;

(b) determining a second radiation wavelength pulsatile value representing the difference between the maximum and the minimum intensity of the pulsatile component of the second radiation wavelength;

20 (c) determining the ratio between the second radiation wavelength pulsatile value and the intensity of the total second radiation wavelength over a period of time;

25 (d) determining a second mean ratio value over a period of time of the ratio between the second radiation wavelength pulsatile component and the average intensity of the second radiation wavelength; and

30 (e) wherein the step of operating to determine the desired biologic constituent concentration of the patient by operating exclusively on the second quantities of the first and second radiation wavelengths comprises the step of determining the desired biologic constituent concentration of the

-29-

patient by the ratio between the first mean ratio value and the second mean ratio value.

4. A method as defined in Claim 1, wherein the step of detecting the second quantity of the first radiation wavelength comprises the steps of:

(a) determining the intensity of the total first radiation wavelength;

(b) determining a first radiation wavelength pulsatile value representing the true time derivative of the pulsatile component of the first radiation wavelength;

(c) determining the ratio between the first radiation wavelength pulsatile value and the intensity of the total first radiation wavelength over a period of time; and

(d) determining a first mean ratio value over a period of time of the ratio between the first radiation wavelength pulsatile component and the average intensity of the first radiation wavelength.

5. A method as defined in Claim 4, wherein the step of detecting the second quantity of the second radiation wavelength comprises the steps of:

(a) determining the intensity of the total second radiation wavelength;

(b) determining a second radiation wavelength pulsatile value representing the true time derivative of the pulsatile component of the second radiation wavelength;

(c) determining the ratio between the second radiation wavelength pulsatile value and the intensity of the total second radiation wavelength over a period of time;

(d) determining a second mean ratio value over a period of time of the ratio between the second radiation wavelength pulsatile component and the

-30-

average intensity of the second radiation wavelength;  
and

5 (e) wherein the step of operating to determine the desired biologic constituent concentration of the patient by operating exclusively on the second quantities of the first and second radiation wavelengths comprises the step of determining the desired biologic constituent concentration of the patient by the ratio between the first mean ratio value and the second mean ratio value.

10 6. A method as defined in Claim 1, wherein the step of operating exclusively on the second quantities of the radiations at the first and second radiation wavelengths to determine the desired biologic constituent concentration of the patient comprises the step of associating the second quantities of the first and second radiation wavelengths with an empirically obtained value.

15 7. A method as defined in Claim 1, wherein the step of operating exclusively on the second quantities of the radiations at the first and second radiation wavelengths to determine the desired biologic constituent concentration of the patient comprises the step of mathematically manipulating the second quantities of the first and second radiation wavelengths with a polynomial function to obtain a desired biologic constituent value.

20 8. A method as defined in Claim 1, wherein the desired biologic constituent comprises red blood cells.

9. A method as defined in Claim 1, wherein the desired biologic constituent comprises hematocrit.

25 10. A method as defined in Claim 1, wherein the desired biologic constituent comprises hemoglobin.

30 11. A method as defined in Claim 1, wherein the first extinguishment value is substantially the same amount for oxyhemoglobin and for reduced hemoglobin in the flowing blood and the second extinguishment value is at least ten

-31-

times smaller than said first extinguishment value for the plasma in the flowing blood.

12. A method as defined in Claim 1, wherein the first radiation wavelength is in the range from about 780  
5 nanometers to about 850 nanometers.

13. A method as defined in Claim 1, wherein the first radiation wavelength is in the range from about 520 nanometers to about 600 nanometers.

14. A method as defined in Claim 1, wherein the third  
10 extinguishment value is substantially the same amount for oxyhemoglobin and for reduced hemoglobin in the flowing blood and the fourth extinguishment value is approximately the same as said third extinguishment value for the plasma in the flowing blood.

15. A method as defined in Claim 1, wherein the  
15 second radiation wavelength is in the range from about 1200 nanometers to about 1600 nanometers.

16. A method as defined in Claim 1, wherein the  
20 flowing blood includes a competing biologic constituent relative to the hemoglobin in the blood, and wherein:

(a) said directed radiation in said step of directing radiation into the flowing blood within the blood conduit further comprises a first quantity of a radiation at a third radiation wavelength, distinct  
25 from said first, second and third radiation wavelengths, and which, when directed into the flowing blood in the blood conduit,

(i) has a fifth extinguishment value which varies with the competing biologic constituent concentration in the flowing blood, said fifth extinguishment value being at least five times greater than said second extinguishment value; and

(ii) has a sixth extinguishment value which  
35 varies with the concentration of components other

-32-

than the competing biologic constituent concentration in the flowing blood;

(b) said detected portion of said directed radiation in said step of detecting further comprises a second quantity of a radiation at the third radiation wavelength;

(c) mathematically operating on the second quantities of the first, second, and third radiation wavelengths such that the spatial, geometric, and tissue variations are eliminated in each radiation wavelength; and

(d) mathematically operating on the second quantities of the first, second, and third radiation wavelengths to compensate for the effect of the competing biologic constituent.

17. A method as defined in Claim 16, wherein the third radiation wavelength is extinguished approximately the same amount by oxyhemoglobin and reduced hemoglobin in the flowing blood and is substantially extinguished by plasma in the flowing blood.

18. A method as defined in Claim 16, wherein the third radiation wavelength is in the range from about 900 nanometers to about 1000 nanometers.

19. A method as defined in Claim 16, further comprising the steps of:

(a) said directed radiation in said step of directing radiation into the flowing blood within the blood conduit further comprises a first quantity of a radiation at a fourth radiation wavelength, distinct from said first, second and third radiation wavelengths, and which, when directed into the flowing blood in the blood conduit,

(i) has a seventh extinguishment value which varies substantially with the oxyhemoglobin

-33-

and reduced oxyhemoglobin concentrations in the flowing blood, and which

(ii) has an eighth extinguishment value, which is at least ten times smaller than said seventh extinguishment value for the plasma in the flowing blood;

(b) said detected portion of said directed radiation in said step of detecting further comprises a second quantity of a radiation at the fourth radiation wavelength;

(c) and further comprising the steps of:

(i) mathematically operating on the second quantity of the fourth radiation wavelength such that the spatial, geometric, and tissue variations are eliminated in the fourth radiation wavelength;

(ii) determining a blood oxygen saturation value which is independent of hematocrit by mathematically operating on the second quantities of the first, second, third, and fourth radiation wavelengths.

20. A method as defined in Claim 19, wherein the fourth radiation wavelength is in the range from about 600 nanometers to about 700 nanometers.

21. A method as defined in Claim 16, wherein:

(a) said directed radiation further comprises a first quantity of a radiation at a fourth radiation wavelength, distinct from said first, second and third radiation wavelengths, which when directed into the flowing blood in the blood conduit,

(i) has a seventh extinguishment value which varies substantially with the oxyhemoglobin and reduced hemoglobin concentrations in the flowing blood, and which

-34-

(ii) has an eighth extinguishment value, which is at least ten times smaller than said seventh extinguishment value for the plasma in the flowing blood;

5 (b) said detected portion of said directed radiation further comprises a second quantity of a radiation at the fourth radiation wavelength;

(c) and further comprising the steps of:

10 (i) mathematically operating on the second quantity of the fourth radiation wavelength such that the spatial, geometric, and tissue variations are eliminated in the fourth radiation wavelength;

15 (ii) determining a blood oxygen saturation value which is independent of hematocrit by mathematically operating on the second quantities of the first, second, third, and fourth radiation wavelengths.

20 22. A method as defined in Claim 21, wherein the fourth radiation wavelength is in the range from about 600 nanometers to about 700 nanometers.

25 23. A method for determining the hematocrit of the blood of a patient, the blood flowing in a pulsatile fashion in a body part of the patient or in an extracorporeal passageway in communication with the circulatory system of the patient so as to be subjectable to transcutaneous examination in the body part or to noninvasive examination in the extracorporeal passageway, the body part and the extracorporeal passageway defining a  
30 blood conduit and the method comprising the steps of:

(a) placing the blood conduit within a blood conduit receiving means with the flowing blood in the blood conduit;

35 (b) directing radiation into the flowing blood within the blood conduit using a radiation generation

-35-

means situated within the blood conduit receiving means, said radiation defining a directed radiation comprising:

5 (i) a first quantity of a radiation at a first radiation wavelength which, when directed into the flowing blood within the blood conduit,

(A) has a first extinguishment value which varies with the hematocrit in the flowing blood and

10 (B) has a second extinguishment value which varies with the plasma in the flowing blood, which second extinguishment value is at least ten times smaller than said first extinguishment value; and

15 (ii) a first quantity of radiation at a second radiation wavelength, distinct from said first wavelength, which, when directed into the flowing blood within the blood conduit,

20 (A) has a third extinguishment value which for varying hematocrit in the flowing blood is a non fixed multiple of said first extinguishment value; and

25 (B) has a fourth extinguishment value which varies with the plasma in the flowing blood, which fourth extinguishment value is at least ten times greater than said second extinguishment value;

30 (c) detecting the portion of said directed radiation which passes through both the blood conduit and the flowing blood therein with a radiation detection means situated within said conduit receiving means, said detected portion of said directed radiation comprising:

35 (i) a second quantity of a radiation at the first radiation wavelength, and

-36-

(ii) a second quantity of a radiation at the second radiation wavelength;

5 (d) operating exclusively on the second quantities of the radiations at the first and second radiation wavelengths to determine the hematocrit of the patient.

24. A method as defined in Claim 23, further comprising the step of displaying the hematocrit.

10 25. A method as defined in Claim 23, wherein the step of operating exclusively on the second quantities of the radiations at the first and second radiation wavelengths to determining the hematocrit of the patient comprises the step of associating the second quantities of the first and second radiation wavelengths with an empirically obtained  
15 value.

26. A method as defined in Claim 23, wherein the step of operating exclusively on the second quantities of the radiations at the first and second radiation wavelengths to determine the hematocrit of the patient comprises the step  
20 of mathematically manipulating the second quantities of the first and second radiation wavelengths with a polynomial function to obtain a hematocrit.

27. A method as defined in Claim 23, wherein the first radiation wavelength is in the range from about 780  
25 nanometers to about 850 nanometers.

28. A method as defined in Claim 23, wherein the first radiation wavelength is in the range from about 520 nanometers to about 600 nanometers.

29. A method as defined in Claim 23, wherein the second radiation wavelength is in the range from about 1200  
30 nanometers to about 1600 nanometers.

30. A method as defined in Claim 23, wherein the flowing blood includes a competing biologic constituent relative to the hemoglobin in the blood, and wherein:

-37-

(a) said directed radiation in said step of directing radiation into the flowing blood within the blood conduit further comprises a first quantity of a radiation at a third radiation wavelength, distinct from said first and second radiation wavelengths, and which, when directed into the flowing blood in the blood conduit,

(i) has a fifth extinguishment value which varies with the competing biologic constituent concentration in the flowing blood, said fifth extinguishment value being at least five times greater than said second extinguishment value; and

(ii) has a sixth extinguishment value which varies with the concentration of components other than the competing biologic constituent concentration in the flowing blood;

(b) said detected portion of said directed radiation in said step of detecting further comprises a second quantity of a radiation at the third radiation wavelength.

31. A method as defined in Claim 30, further comprising the step of:

(a) operating on the second quantity of radiation at the third radiation wavelength and the hematocrit determined in said step of operating exclusively on the second quantities of the radiations at the first and second wavelengths to determine a corrected hematocrit of the patient; and

(b) displaying the corrected hematocrit of the patient.

32. A method as defined in Claim 30, further comprising the step of varying the directed radiation on the basis of the detected portion of the directed

-38-

radiation, thereby to maintain the detected portion of the directed radiation within a predetermined range.

33. A method as defined in Claim 30, wherein the third radiation wavelength is in the range from 900  
5 nanometers to 1000 nanometers.

34. A method as defined in Claim 30, wherein:

(a) said directed radiation in said step of directing radiation into the flowing blood within the blood conduit further comprises a first quantity of a  
10 radiation at a fourth radiation wavelength, distinct from said first, second and third radiation wavelengths, and which, when directed into the flowing blood in the blood conduit,

(i) has a seventh extinguishment value  
15 which varies substantially with the oxyhemoglobin and reduced oxyhemoglobin concentrations in the flowing blood, and which

(ii) has an eighth extinguishment value, which is at least ten times smaller than said  
20 seventh extinguishment value for the plasma in the flowing blood.

(b) said detected portion of said directed radiation in said step of detecting further comprises a second quantity of a radiation at the fourth  
25 radiation wavelength.

35. A method as defined in Claim 34, further comprising the steps of:

(a) determining a hematocrit independent blood oxygen saturation value by the second quantities of  
30 the first, second, third, and fourth radiation wavelengths; and

(b) displaying the hematocrit independent blood oxygen saturation value.

-39-

36. A method as defined in Claim 35, wherein the fourth radiation wavelength is in the range from 600 nanometers to 700 nanometers.

5 37. A method as defined in Claim 35, wherein the radiation generation means is situated opposite the radiation detection means, whereby the first, second, third, and fourth radiation wavelengths are transmitted through the blood conduit.

10 38. A method as defined in Claim 35, wherein the radiation generation means is not situated opposite the radiation detection means, whereby the first, second, third, and fourth radiation wavelengths are reflected from the blood conduit.

15 39. A system for determining the hematocrit of the blood of a patient, the blood flowing in a pulsatile fashion in a body part of the patient or in an extracorporeal passageway in communication with the circulatory system of the patient so as to be subjectable to transcutaneous examination in the body part or to  
20 noninvasive examination in the extracorporeal passageway, the body part and the extracorporeal passageway defining a blood conduit and the system comprising:

25 (a) a blood conduit receiving means for receiving a blood conduit containing the flowing blood of the patient;

(b) emission means for directing radiation into the flowing blood within the blood conduit, said emission means being situated within said blood conduit receiving means, said radiation defining a  
30 directed radiation comprising:

(i) a first quantity of a radiation at a first radiation wavelength which, when directed into the flowing blood in the blood conduit,

-40-

(A) has a first extinguishment value which varies with the hematocrit in the flowing blood and

5 (B) has a second extinguishment value which varies with the plasma in the flowing blood, which second extinguishment value is at least ten times smaller than said first extinguishment value; and

10 (ii) a first quantity of radiation at a second radiation wavelength, distinct from said first wavelength, which, when directed into the flowing blood within the blood conduit,

15 (A) has a third extinguishment value which for varying hematocrit in the flowing blood is a non fixed multiple of said first extinguishment value; and

20 (B) has a fourth extinguishment value which varies with the plasma in the flowing blood, which fourth extinguishment value is at least ten times greater than said second extinguishment value;

(c) detection means for detecting the portion of said directed radiation which passes through both the blood conduit and the flowing blood therein, said  
25 detection means being situated within said blood conduit receiving means, said detected portion of said directed radiation comprising:

(i) a second quantity of a radiation at the first radiation wavelength, and

30 (ii) a second quantity of a radiation at the second radiation wavelength;

(d) calculation means for determining the hematocrit of the patient by operating exclusively on the second quantities of the first and second  
35 radiation wavelengths.

-41-

40. A system as defined in Claim 39, wherein said detection means detects the second quantity of the first radiation wavelength by:

5 (a) determining the intensity of the total first radiation wavelength;

(b) determining a first radiation wavelength pulsatile value representing the difference between the maximum and the minimum intensity of the pulsatile component of the first radiation wavelength;

10 (c) determining the ratio between the first radiation wavelength pulsatile value and the intensity of the total first radiation wavelength over a period of time; and

15 (d) determining a first mean ratio value over a period of time of the ratio between the first radiation wavelength pulsatile component and the average intensity of the first radiation wavelength.

41. A system as defined in Claim 40, wherein said detection means detects the second quantity of the second radiation wavelength by:

20 (a) determining the intensity of the total second radiation wavelength;

25 (b) determining a second radiation wavelength pulsatile value representing the difference between the maximum and the minimum intensity of the pulsatile component of the second radiation wavelength;

30 (c) determining the ratio between the second radiation wavelength pulsatile value and the intensity of the total second radiation wavelength over a period of time;

35 (d) determining a second mean ratio value over a period of time of the ratio between the second radiation wavelength pulsatile component and the average intensity of the second radiation wavelength; and

-42-

5 (e) wherein the calculation means determines the hematocrit of the patient by operating exclusively on the second quantities of the first and second radiation wavelengths to determine the hematocrit of the patient by the ratio between the first mean ratio value and the second mean ratio value.

42. A system as defined in Claim 39, wherein the detection means detects the second quantity of the first radiation wavelength by:

10 (a) determining the intensity of the total first radiation wavelength;

(b) determining a first radiation wavelength pulsatile value representing the true time derivative of the pulsatile component of the first radiation wavelength;

15

(c) determining the ratio between the first radiation wavelength pulsatile value and the intensity of the total first radiation wavelength over a period of time; and

20 (d) determining a first mean ratio value over a period of time of the ratio between the first radiation wavelength pulsatile component and the average intensity of the first radiation wavelength.

25 43. A system as defined in Claim 42, wherein the detection means detects the second quantity of the second radiation wavelength by:

(a) determining the intensity of the total second radiation wavelength;

(b) determining a second radiation wavelength pulsatile value representing the true time derivative of the pulsatile component of the second radiation wavelength;

30

(c) determining the ratio between the second radiation wavelength pulsatile value and the intensity

-43-

of the total second radiation wavelength over a period of time;

5 (d) determining a second mean ratio value over a period of time of the ratio between the second radiation wavelength pulsatile component and the average intensity of the second radiation wavelength; and

10 (e) wherein the calculation means determines the hematocrit of the patient by operating exclusively on the second quantities of the first and second radiation wavelengths to determine the hematocrit of the patient by the ratio between the first mean ratio value and the second mean ratio value.

15 44. A system as defined in Claim 39, wherein the calculation means determines the hematocrit of the patient by associating the second quantities of the first and second radiation wavelengths with an empirically obtained value.

20 45. A system as defined in Claim 39, wherein said calculation means determines the hematocrit of the patient by mathematically manipulating the second quantities of the first and second radiation wavelengths with a polynomial function to obtain a hematocrit.

25 46. A system as defined in Claim 39, further comprising means for displaying the hematocrit.

47. A system as defined in Claim 46, wherein the display means comprises a visually perceptible display.

48. A system as defined in Claim 39, wherein the first radiation wavelength is in the range from 780 nanometers to 850 nanometers.

5 49. A system as defined in Claim 39, wherein the first radiation wavelength is in the range from 520 nanometers to 600 nanometers.

50. A system as defined in Claim 39, wherein the second radiation wavelength is in the range from 1200 nanometers to 1600 nanometers.

10 51. A system as defined in Claim 39, wherein the flowing blood includes a competing biologic constituent relative to the hemoglobin in the flowing blood, wherein:

15 (a) said directed radiation further comprises a first quantity of a radiation at a third radiation wavelength, distinct from said first and second radiation wavelengths, and which, when directed into the flowing blood in the blood conduit,

20 (i) has a fifth extinguishment value which varies with the competing biologic constituent concentration in the flowing blood, said fifth extinguishment value being at least five times greater than said second extinguishment value; and

25 (ii) has a sixth extinguishment value which varies with the concentration of components other than the competing biologic constituent concentration in the flowing blood;

30 (b) said detected portion of said directed radiation further comprises a second quantity of a radiation at the third radiation wavelength; and

35 (c) wherein the calculation means mathematically operates on the second quantities of the first, second, and third radiation wavelengths to compensate for the effect of the competing blood constituent so as to determine a corrected hematocrit.

-45-

52. A system as defined in Claim 51, wherein the third radiation wavelength is in the range from 900 nanometers to 1000 nanometers.

53. A system as defined in Claim 52, wherein:

5 (a) said directed radiation further comprises a first quantity of a radiation at a fourth radiation wavelength, distinct from said first, second and third radiation wavelengths, which when directed into the flowing blood in the blood conduit,

10 (i) has a seventh extinguishment value which varies substantially with the oxyhemoglobin and reduced oxyhemoglobin concentrations in the flowing blood, and which

15 (ii) has an eighth extinguishment value, which is at least ten times smaller than said seventh extinguishment value for the plasma in the flowing blood;

20 (b) said detected portion of said directed radiation further comprises a second quantity of a radiation at the fourth radiation wavelength.

54. A system as defined in Claim 53:

25 (a) wherein the calculation means is also capable of determining the patient's blood oxygen saturation by the second quantities of the first, second, third, and fourth radiation wavelengths; and

(b) further comprising a display means wherein the display means is also capable of displaying a value of the blood oxygen saturation which is independent of hematocrit.

30 55. A system as defined in Claim 53, wherein the fourth radiation wavelength is in the range from 600 nanometers to 700 nanometers.

-46-

56. A system as defined in Claim 53, wherein the radiation generation means is situated opposite the radiation detection means, whereby the first, second, third, and fourth radiation wavelengths are transmitted through the blood conduit.

57. A system as defined in Claim 53, wherein the radiation generation means is not situated opposite the radiation detection means, whereby the first, second, third, and fourth radiation wavelengths are reflected from the blood conduit.

58. A system as defined in Claim 53:

(a) wherein the calculation means is also capable of determining the patient's blood oxygen content by the second quantities of the first, second, third, and fourth radiation wavelengths; and

(b) further comprising a display means wherein the display means is also capable of displaying a value of the blood oxygen content.

59. A system as defined in Claim 39, further comprising pressure means for squeezing at least some of the flowing blood out of the blood conduit while radiation having the first and second radiation wavelengths are being directed into the blood conduit.

60. A system as defined in Claim 39, wherein the emission means comprises at least two light emitting diodes.

61. A system as defined in Claim 39, wherein the emission means comprises at least two laser diodes.

62. A system as defined in Claim 39, wherein the detection means comprises at least one photodetector.

63. A system as defined in Claim 39, wherein the calculation means comprises a microprocessor and at least one analog to digital convertor.

64. A system for determining the hematocrit of the blood of a patient, the blood flowing in a pulsatile

-47-

fashion in a body part of the patient or in an extracorporeal passageway in communication with the circulatory system of the patient so as to be subjectable to transcutaneous examination in the body part or to  
5 noninvasive examination in the extracorporeal passageway, the body part and the extracorporeal passageway defining a blood conduit, the system comprising:

(a) a blood conduit receiving means for receiving a blood conduit containing the flowing blood  
10 of the patient;

(b) first optical emitter means for directing radiation into the flowing blood within the blood conduit, said first optical emitter means being situated within said blood conduit receiving means,  
15 said radiation defining a first directed radiation comprising:

(i) a first quantity of a radiation at a first radiation wavelength which, when directed into the flowing blood in the blood conduit,

20 (A) is near isobestic for oxyhemoglobin and reduced hemoglobin in the flowing blood and has a first extinguishment value which varies with the hematocrit in the flowing blood and

25 (B) has a second extinguishment value which varies with the plasma in the flowing blood, which second extinguishment value is at least ten times smaller than said first extinguishment value;

30 (c) second optical emitter means for directing radiation into the flowing blood within the blood conduit, said second optical emitter emission means being situated within said blood conduit receiving means, said radiation defining a second directed  
35 radiation comprising:

-48-

(i) a first quantity of radiation at a second radiation wavelength, distinct from said first wavelength, which, when directed into the flowing blood within the blood conduit,

5 (A) has a third extinguishment value which for varying hematocrit in the flowing blood is a non fixed multiple of said first extinguishment value; and

10 (B) has a fourth extinguishment value which varies with the plasma in the flowing blood, which fourth extinguishment value is at least ten times greater than said second extinguishment value;

15 (d) third optical emitter means for directing radiation into the flowing blood within the blood conduit, said third optical emitter emission means being situated within said blood conduit receiving means, said radiation defining a third directed radiation comprising:

20 (i) a first quantity of a radiation at a third radiation wavelength distinct from said first and second radiation wavelengths and which, in combination with one of the first or second radiation wavelengths, is independent of  
25 hematocrit, and which, when directed into the flowing blood in the blood conduit,

(A) has a fifth extinguishment value which varies with the competing biologic constituent concentration in the flowing  
30 blood, said fifth extinguishment value being at least five times greater than said second extinguishment value; and

(B) has a sixth extinguishment value which varies with the concentration of  
35 components other than the competing biologic

-49-

constituent concentration in the flowing blood;

(e) photodetection means for detecting the portion of said first, second and third directed radiation which passes through both the blood conduit and the flowing blood therein, said photodetection means being situated within said blood conduit receiving means, said detected portions comprising:

(i) a second quantity of a radiation at the first radiation wavelength,

(ii) a second quantity of a radiation at the second radiation wavelength,

(iii) a second quantity of a radiation at the third radiation wavelength; and

(f) positioning means for holding the first optical emitter means, the second optical emitter means, the third optical emitter means, and the photodetection means such that the radiation path from the first, second, and third optical emitter means to the photodetection means are approximately equal;

(g) calculation means

(i) for mathematically operating on the second quantities to the first, second, and third radiation wavelengths such that the spatial, geometric, and tissue variations are eliminated in each wavelength

(ii) for mathematically operating on the second quantities of the first, second, and third radiation wavelengths to compensate for the effect of the competing blood constituent, and

(iii) for determining the hematocrit of the patient; and

(h) display means for providing a visually perceptible indication of the hematocrit.

-50-

65. A system as defined in Claim 64, further comprising:

5 (a) fourth optical emitter means for directing radiation into the flowing blood within the blood conduit, said fourth optical emitter means being situated within said blood conduit receiving means, said radiation defining a fourth directed radiation and comprising:

10 (i) a first quantity of a radiation at a fourth radiation wavelength which, when directed into the flowing blood within the blood conduit,

15 (A) has a seventh extinguishment value which varies substantially with the oxyhemoglobin and reduced oxyhemoglobin concentrations in the flowing blood, and which

20 (B) has an eighth extinguishment value, which is at least ten times smaller than said seventh extinguishment value for the plasma in the flowing blood;

25 (ii) wherein the photodetection means detects the portion of said fourth directed radiation which passes through both the blood conduit and the flowing blood therein, said detected portion of said fourth radiation wavelength comprising a second quantity of the fourth radiation wavelength.

66. A system as defined in Claim 65:

30 (a) wherein the calculation means mathematically operates on the second quantity of the fourth radiation wavelength to determine the patient's blood oxygen saturation; and

35 (b) wherein the display means displays a value of the blood oxygen saturation which is independent of hematocrit.

-51-

67. A system as defined in Claim 65:

(a) wherein the calculation means mathematically operates on the second quantity of the fourth radiation wavelength to determine the patient's blood oxygen content; and

(b) wherein the display means displays a value of the blood oxygen content.

68. A system for determining the desired biologic constituent concentration of the blood of a patient, the blood flowing in a pulsatile fashion in a body part of the patient or in an extracorporeal passageway in communication with the circulatory system of the patient so as to be subjectable to transcutaneous examination in the body part or to noninvasive examination in the extracorporeal passageway, the body part and the extracorporeal passageway defining a blood conduit, the system comprising:

(a) a blood conduit receiving means for receiving a blood conduit containing the flowing blood of the patient;

(b) emission means for directing radiation into the flowing blood within the blood conduit, said emission means being situated within said blood conduit receiving means, said radiation defining a directed radiation comprising:

(i) a first quantity of a radiation at a first radiation wavelength which, when directed into the flowing blood within the blood conduit,

(A) has a first extinguishment value which varies with the desired biologic constituent concentration in the flowing blood and

(B) has a second extinguishment value which varies with the concentration of components other than the desired biologic constituent in the flowing blood, which

-52-

second extinguishment value is at least ten times smaller than said first extinguishment value; and

5 (ii) a first quantity of a radiation at a second radiation wavelength, distinct from said first wavelength, which, when directed into the flowing blood within the blood conduit,

10 (A) has a third extinguishment value which for varying concentrations in the flowing blood of the desired blood constituent is a non fixed multiple of said first extinguishment value and

15 (B) has a fourth extinguishment value which varies with the concentration of components other than the desired biologic constituent in the flowing blood, which fourth extinguishment value is at least ten times greater than said second extinguishment value;

20 (c) detection means for detecting the portion of said directed radiation which passes through both the blood conduit and the flowing blood therein, said detection means being situated within said blood conduit receiving means, said detected portion of said  
25 directed radiation comprising:

(i) a second quantity of a radiation at the first radiation wavelength, and

(ii) a second quantity of a radiation at the second radiation wavelength;

30 (d) calculation means for determining the desired biologic constituent concentration by operating exclusively on the second quantities of the first and second radiation wavelengths.

-53-

69. A system as defined in Claim 68, wherein said detection means detects the second quantity of the first radiation wavelength by:

5 (a) determining the intensity of the total first radiation wavelength;

(b) determining a first radiation wavelength pulsatile value representing the difference between the maximum and the minimum intensity of the pulsatile component of the first radiation wavelength;

10 (c) determining the ratio between the first radiation wavelength pulsatile value and the intensity of the total first radiation wavelength over a period of time; and

15 (d) determining a first mean ratio value over a period of time of the ratio between the first radiation wavelength pulsatile component and the average intensity of the first radiation wavelength.

70. A system as defined in Claim 69, wherein the detection means detects the second quantity of the first radiation wavelength by:

20 (a) determining the intensity of the total first radiation wavelength;

25 (b) determining a first radiation wavelength pulsatile value representing the true time derivative of the pulsatile component of the first radiation wavelength;

30 (c) determining the ratio between the first radiation wavelength pulsatile value and the intensity of the total first radiation wavelength over a period of time; and

(d) determining a first mean ratio value over a period of time of the ratio between the first radiation wavelength pulsatile component and the average intensity of the first radiation wavelength.

-54-

71. A system as defined in Claim 70, wherein said detection means detects the second quantity of the second radiation wavelength by:

5 (a) determining the intensity of the total second radiation wavelength;

(b) determining a second radiation wavelength pulsatile value representing the difference between the maximum and the minimum intensity of the pulsatile component of the second radiation wavelength;

10 (c) determining the ratio between the second radiation wavelength pulsatile value and the intensity of the total second radiation wavelength over a period of time;

15 (d) determining a second mean ratio value over a period of time of the ratio between the second radiation wavelength pulsatile component and the average intensity of the second radiation wavelength; and

20 (e) wherein the calculation means determines the desired biologic constituent concentration of the patient by operating exclusively on the second quantities of the first and second radiation wavelengths to determine the desired biologic constituent concentration of the patient by the ratio  
25 between the first mean ratio value and the second mean ratio value.

72. A system as defined in Claim 71, wherein the detection means detects the second quantity of the second radiation wavelength by:

30 (a) determining the intensity of the total second radiation wavelength;

(b) determining a second radiation wavelength pulsatile value representing the true time derivative of the pulsatile component of the second radiation  
35 wavelength;

-55-

(c) determining the ratio between the second radiation wavelength pulsatile value and the intensity of the total second radiation wavelength over a period of time;

5 (d) determining a second mean ratio value over a period of time of the ratio between the second radiation wavelength pulsatile component and the average intensity of the second radiation wavelength; and

10 (e) wherein the calculation means determines the desired biologic constituent concentration of the patient by operating exclusively on the second quantities of the first and second radiation wavelengths to determine the desired biologic  
15 constituent concentration of the patient by the ratio between the first mean ratio value and the second mean ratio value.

73. A system as defined in Claim 68, wherein the calculation means determines the desired biologic  
20 constituent concentration of the patient by associating the second quantities of the first and second radiation wavelengths with an empirically obtained value.

74. A system as defined in Claim 68, wherein said calculation means determines the desired biologic  
25 constituent concentration of the patient by mathematically manipulating the second quantities of the first and second radiation wavelengths with a polynomial function to obtain the desired biologic constituent concentration.

75. A system as defined in Claim 68, wherein the  
30 desired biologic constituent comprises red blood cells.

76. A system as defined in Claim 68, wherein the desired biologic constituent comprises hematocrit.

77. A system as defined in Claim 68, wherein the desired biologic constituent comprises hemoglobin.

-56-

78. A system as defined in Claim 68, wherein the first radiation wavelength has a first extinguishment value substantially the same amount for oxyhemoglobin and for reduced hemoglobin in the flowing blood and has a second  
5 extinguishment value, which is at least ten times smaller than said first extinguishment value for the plasma in the flowing blood.

79. A system as defined in Claim 68, wherein the first radiation wavelength is in the range from about 780  
10 nanometers to about 850 nanometers.

80. A system as defined in Claim 68, wherein the first radiation wavelength is in the range from about 520 nanometers to about 600 nanometers.

81. A system as defined in Claim 68, wherein the  
15 second radiation wavelength has a third extinguishment value substantially the same amount for oxyhemoglobin and for reduced hemoglobin in the flowing blood and has a fourth extinguishment value, which is approximately the same as said third extinguishment value for the plasma in  
20 the flowing blood.

82. A system as defined in Claim 68, wherein the second radiation wavelength is in the range from about 1200 nanometers to about 1600 nanometers.

83. A system as defined in Claim 68, wherein the  
25 flowing blood includes a competing biologic constituent relative to the hemoglobin in the flowing blood, wherein:

(a) said directed radiation further comprises a first quantity of a radiation at a third radiation wavelength, distinct from said first, second, and  
30 third radiation wavelengths, and which, when directed into the flowing blood in the blood conduit,

(i) has a fifth extinguishment value which varies with the competing biologic constituent concentration in the flowing blood, said fifth  
35 extinguishment value being at least five times

-57-

greater than said second extinguishment value;  
and

5 (ii) has a sixth extinguishment value which  
varies with the concentration of components other  
than the competing biologic constituent  
concentration in the flowing blood;

(b) said detected portion of said directed  
radiation further comprises a second quantity of a  
radiation at the third radiation wavelength;

10 (c) said system further comprising calculation  
means for mathematically operating on the second  
quantities of the first, second, and third radiation  
wavelengths

15 (i) such that the spatial, geometric, and  
tissue variations are eliminated in each  
radiation wavelength; and

(ii) to compensate for the effect of the  
competing biologic constituent.

20 84. A system as defined in Claim 83, wherein the  
third radiation wavelength is extinguished approximately  
the same amount by oxyhemoglobin and reduced hemoglobin in  
the flowing blood and is substantially extinguished by  
plasma in the flowing blood.

25 85. A system as defined in Claim 83, wherein the third  
radiation wavelength is in the range from about 900  
nanometers to about 1000 nanometers.

86. A system as defined in Claim 83, wherein:

30 (a) said directed radiation further comprises a  
first quantity of a radiation at a fourth radiation  
wavelength, distinct from said first, second and third  
radiation wavelengths, which when directed into the  
flowing blood in the blood conduit;

(i) has a seventh extinguishment value  
which varies substantially with the oxyhemoglobin

-58-

and reduced oxyhemoglobin concentrations in the flowing blood, and which

(ii) has an eighth extinguishment value, which is at least ten times smaller than said seventh extinguishment value for the plasma in the flowing blood;

(b) said detected portion of said directed radiation further comprises a second quantity of a radiation at the fourth radiation wavelength;

(c) and wherein said calculation means:

(i) mathematically operates on the second quantity of the fourth radiation wavelength such that the spatial, geometric, and tissue variations are eliminated in the fourth radiation wavelength, and

(ii) determines a blood oxygen saturation value which is independent of hematocrit by mathematically operating on the second quantities of the first, second, third, and fourth radiation wavelengths.

87. A system as defined in Claim 86, wherein the fourth radiation wavelength is in the range from about 600 nanometers to about 700 nanometers.

88. A system as defined in Claim 83, wherein:

(a) said directed radiation further comprises a first quantity of a radiation at a fourth radiation wavelength, distinct from said first, second and third radiation wavelengths, which when directed into the flowing blood in the blood conduit,

(i) has a seventh extinguishment value which varies substantially with the oxyhemoglobin and reduced hemoglobin concentrations in the flowing blood, and which

(ii) has an eighth extinguishment value, which is at least ten times smaller than said

-59-

seventh extinguishment value for the plasma in the flowing blood;

(b) said detected portion of said directed radiation further comprises a second quantity of a radiation at the fourth radiation wavelength;

(c) and wherein said calculation means:

(i) mathematically operates on the second quantity of the fourth radiation wavelength such that the spatial, geometric, and tissue variations are eliminated in the fourth radiation wavelength; and

(ii) determines a blood oxygen saturation value which is independent of hematocrit by mathematically operating on the second quantities of the first, second, third, and fourth radiation wavelengths.

89. A system as defined in Claim 88, wherein the fourth radiation wavelength is in the range from about 600 nanometers to about 700 nanometers.

90. A method for determining the hematocrit of the blood of a patient, the blood flowing in a pulsatile fashion in a body part of the patient or in an extracorporeal passageway in communication with the circulatory system of the patient so as to be subjectable to transcutaneous examination in the body part or to noninvasive examination in the extracorporeal passageway, the body part and the extracorporeal passageway defining a blood conduit and the method comprising the steps of:

(a) placing the blood conduit within a blood conduit receiving means with the flowing blood in the blood conduit;

(b) directing radiation into the flowing blood within the blood conduit using a radiation generation means situated within the blood conduit receiving

-60-

means, said radiation defining a directed radiation comprising:

5 (i) a first quantity of a radiation at a first radiation wavelength which, when directed into the flowing blood within the blood conduit,

(A) is extinguished substantially the same amount by oxyhemoglobin and reduced hemoglobin in the flowing blood and

10 (B) is extinguished by the plasma in the flowing blood in a first manner; and

(ii) a first quantity of radiation at a second radiation wavelength which, when directed into the flowing blood within the blood conduit,

15 (A) is extinguished substantially the same amount by oxyhemoglobin and reduced hemoglobin in the flowing blood and

20 (B) is extinguished by the plasma in the flowing blood in a second manner substantially different from said first manner;

(c) detecting the portion of said directed radiation which passes through both the blood conduit and the flowing blood therein with a radiation detection means situated within said conduit receiving means, said detected portion of said directed radiation comprising:

25 (i) a second quantity of a radiation at the first radiation wavelength being detected by steps comprising:

30 (A) determining the extinguishment of the total first radiation wavelength;

(B) determining a first radiation wavelength pulsatile value representing the difference between the maximum and the

-61-

minimum extinguishment of the pulsatile component of the first radiation wavelength;

(C) determining the ratio between the first radiation wavelength pulsatile value and the extinguishment of the total first radiation wavelength over a period of time; and

(D) determining a first mean ratio value over a period of time of the ratio between the first radiation wavelength pulsatile component and the average extinguishment of the first radiation wavelength, and

(ii) a second quantity of a radiation at the second radiation wavelength;

(d) operating on the second quantities of the radiations at the first and second radiation wavelengths to determine the hematocrit of the patient.

91. A method as defined in Claim 90, wherein the step of detecting the second quantity of the second radiation wavelength comprises the steps of:

(a) determining the extinguishment of the total second radiation wavelength;

(b) determining a second radiation wavelength pulsatile value representing the difference between the maximum and the minimum extinguishment of the pulsatile component of the second radiation wavelength;

(c) determining the ratio between the second radiation wavelength pulsatile value and the extinguishment of the total second radiation wavelength over a period of time;

-62-

(d) determining a second mean ratio value over a period of time of the ratio between the second radiation wavelength pulsatile component and the average extinguishment of the second radiation wavelength; and

(e) wherein the step of determining the hematocrit of the patient by operating on the second quantities of the first and second radiation wavelengths comprises the step of determining the hematocrit of the patient by the ratio between the first mean ratio value and the second mean ratio value.

92. A method for determining the hematocrit of the blood of a patient, the blood flowing in a pulsatile fashion in a body part of the patient or in an extracorporeal passageway in communication with the circulatory system of the patient so as to be subjectable to transcutaneous examination in the body part or to noninvasive examination in the extracorporeal passageway, the body part and the extracorporeal passageway defining a blood conduit and the method comprising the steps of:

(a) placing the blood conduit within a blood conduit receiving means with the flowing blood in the blood conduit;

(b) directing radiation into the flowing blood within the blood conduit using a radiation generation means situated within the blood conduit receiving means, said radiation defining a directed radiation comprising:

(i) a first quantity of a radiation at a first radiation wavelength which, when directed into the flowing blood within the blood conduit,

(A) is extinguished substantially the same amount by oxyhemoglobin and reduced hemoglobin in the flowing blood and

-63-

(B) is extinguished by the plasma in the flowing blood in a first manner; and  
(ii) a first quantity of radiation at a second radiation wavelength which, when directed  
5 into the flowing blood within the blood conduit,

(A) is extinguished substantially the same amount by oxyhemoglobin and reduced hemoglobin in the flowing blood and

(B) is extinguished by the plasma in the flowing blood in a second manner substantially different from said first manner;

(c) detecting the portion of said directed radiation which passes through both the blood conduit and the flowing blood therein with a radiation  
15 detection means situated within said conduit receiving means, said detected portion of said directed radiation comprising:

(i) a second quantity of a radiation at the first radiation wavelength, and

(ii) a second quantity of a radiation at the second radiation wavelength being detected by steps comprising:

(A) determining the extinguishment of the total first radiation wavelength;

(B) determining a first radiation wavelength pulsatile value representing the true time derivative of the pulsatile component of the first radiation wavelength;

(C) determining the ratio between the first radiation wavelength pulsatile value and the extinguishment of the total first radiation wavelength over a period of time; and

-64-

5 (D) determining a first mean ratio value over a period of time of the ratio between the first radiation wavelength pulsatile component and the average extinguishment of the first radiation wavelength;

10 (d) operating on the second quantities of the radiations at the first and second radiation wavelengths to determine the hematocrit of the patient.

93. A method as defined in Claim 92, wherein the step of detecting the second quantity of the second radiation wavelength comprises the steps of:

15 (a) determining the extinguishment of the total second radiation wavelength;

(b) determining a second radiation wavelength pulsatile value representing the true time derivative of the pulsatile component of the second radiation wavelength;

20 (c) determining the ratio between the second radiation wavelength pulsatile value and the extinguishment of the total second radiation wavelength over a period of time;

25 (d) determining a second mean ratio value over a period of time of the ratio between the second radiation wavelength pulsatile component and the average extinguishment of the second radiation wavelength; and

30 (e) wherein the step of determining the hematocrit of the patient by operating on the second quantities of the first and second radiation wavelengths comprises the step of determining the hematocrit of the patient by the ratio between the first mean ratio value and the second mean ratio value.  
35

-65-

94. A method for determining the hematocrit of the flowing blood of a patient, the flowing blood including a competing biologic constituent relative to the hemoglobin in the blood, the blood flowing in a pulsatile fashion in a body part of the patient or in an extracorporeal passageway in communication with the circulatory system of the patient so as to be subjectable to transcutaneous examination in the body part or to noninvasive examination in the extracorporeal passageway, the body part and the extracorporeal passageway defining a blood conduit and the method comprising the steps of:

(a) placing the blood conduit within a blood conduit receiving means with the flowing blood in the blood conduit;

(b) directing radiation into the flowing blood within the blood conduit using a radiation generation means situated within the blood conduit receiving means, said radiation defining a directed radiation comprising:

(i) a first quantity of a radiation at a first radiation wavelength which, when directed into the flowing blood within the blood conduit,

(A) is extinguished substantially the same amount by oxyhemoglobin and reduced hemoglobin in the flowing blood and

(B) is extinguished by the plasma in the flowing blood in a first manner;

(ii) a first quantity of radiation at a second radiation wavelength which, when directed into the flowing blood within the blood conduit,

(A) is extinguished substantially the same amount by oxyhemoglobin and reduced hemoglobin in the flowing blood and

(B) is extinguished by the plasma in the flowing blood in a second manner

-66-

substantially different from said first manner; and

(iii) a first quantity of a radiation at a third radiation wavelength, which when directed into the flowing blood in the blood conduit,

(A) is extinguished by the competing biologic constituent in the flowing blood in a manner characteristic of the competing biologic constituent; and

(B) is extinguished by the constituents of the flowing blood other than the competing biologic constituent in a third manner, said third manner being substantially different from one of said first and second manners;

(c) detecting the portion of said directed radiation which passes through both the blood conduit and the flowing blood therein with a radiation detection means situated within said conduit receiving means, said detected portion of said directed radiation comprising:

(i) a second quantity of a radiation at the first radiation wavelength,

(ii) a second quantity of a radiation at the second radiation wavelength, and

(iii) a second quantity of a radiation at the third radiation wavelength being detected by steps comprising:

(A) determining the extinguishment of the total third radiation wavelength;

(B) determining a third radiation wavelength pulsatile value representing the difference between the maximum and the minimum extinguishment of the pulsatile component of the third radiation wavelength;

-67-

(C) determining the ratio between the third radiation wavelength pulsatile value and the extinguishment of the total third radiation wavelength over a period of time;

5 (D) determining a third mean ratio value over a period of time of the ratio between the third radiation wavelength pulsatile component and the average extinguishment of the third radiation wavelength;

10

(d) operating on the second quantities of the radiations at the first and second and third radiation wavelengths to determine the corrected hematocrit of the patient by determining the hematocrit of the patient by the combination of the first, second, and

15 third mean ratio values.

95. A method as defined in Claim 94, wherein the first, second and third mean ratio values are combined linearly.

20 96. A method for determining the hematocrit of the flowing blood of a patient, the flowing blood including a competing biologic constituent relative to the hemoglobin in the blood, the blood flowing in a pulsatile fashion in a body part of the patient or in an extracorporeal passageway in communication with the circulatory system of the patient so as to be subjectable to transcutaneous examination in the body part or to noninvasive examination in the extracorporeal passageway, the body part and the extracorporeal passageway defining a blood conduit and the

25 method comprising the steps of:

30

(a) placing the blood conduit within a blood conduit receiving means with the flowing blood in the blood conduit;

(b) directing radiation into the flowing blood

35 within the blood conduit using a radiation generation

-68-

means situated within the blood conduit receiving means, said radiation defining a directed radiation comprising:

5 (i) a first quantity of a radiation at a first radiation wavelength which, when directed into the flowing blood within the blood conduit,

(A) is extinguished substantially the same amount by oxyhemoglobin and reduced hemoglobin in the flowing blood and

10 (B) is extinguished by the plasma in the flowing blood in a first manner;

(ii) a first quantity of radiation at a second radiation wavelength which, when directed into the flowing blood within the blood conduit,

15 (A) is extinguished substantially the same amount by oxyhemoglobin and reduced hemoglobin in the flowing blood and

(B) is extinguished by the plasma in the flowing blood in a second manner substantially different from said first manner; and

20 (iii) first quantity of a radiation at a third radiation wavelength, which when directed into the flowing blood in the blood conduit,

25 (A) is extinguished by the competing biologic constituent in the flowing blood in a manner characteristic of the competing biologic constituent; and

30 (B) is extinguished by the constituents of the flowing blood other than the competing biologic constituent in a third manner, said third manner being substantially different from one of said first and second manners;

-69-

(c) detecting the portion of said directed radiation which passes through both the blood conduit and the flowing blood therein with a radiation detection means situated within said conduit receiving means, said detected portion of said directed radiation comprising:

(i) a second quantity of a radiation at the first radiation wavelength,

(ii) a second quantity of a radiation at the second radiation wavelength, and

(iii) a second quantity of a radiation at the third radiation wavelength being detected by steps comprising:

(A) determining the extinguishment of the total third radiation wavelength;

(B) determining a third radiation wavelength pulsatile value representing the true time derivative of the pulsatile component of the third radiation wavelength;

(C) determining the ratio between the third radiation wavelength pulsatile value and the extinguishment of the total third radiation wavelength over a period of time;

(D) determining a third mean ratio value over a period of time of the ratio between the third radiation wavelength pulsatile component and the average extinguishment of the third radiation wavelength;

(d) operating on the second quantities of the radiations at the first and second and third radiation wavelengths to determine the corrected hematocrit of the patient by determining the hematocrit of the patient by the combination of the first, second, and third mean ratio values.

97. A method as defined in Claim 96, wherein the first, second, and third mean ratio values are combined linearly.

5 98. A method for determining the hematocrit of the flowing blood of a patient, the flowing blood including a competing biologic constituent relative to the hemoglobin in the blood, the blood flowing in a pulsatile fashion in a body part of the patient or in an extracorporeal passageway in communication with the circulatory system of  
10 the patient so as to be subjectable to transcutaneous examination in the body part or to noninvasive examination in the extracorporeal passageway, the body part and the extracorporeal passageway defining a blood conduit and the method comprising the steps of:

15 (a) placing the blood conduit within a blood conduit receiving means with the flowing blood in the blood conduit;

(b) directing radiation into the flowing blood within the blood conduit using a radiation generation  
20 means situated within the blood conduit receiving means, said radiation defining a directed radiation comprising:

(i) a first quantity of a radiation at a first radiation wavelength which, when directed  
25 into the flowing blood within the blood conduit,

(A) is extinguished substantially the same amount by oxyhemoglobin and reduced hemoglobin in the flowing blood and

(B) is extinguished by the plasma in  
30 the flowing blood in a first manner;

(ii) a first quantity of radiation at a second radiation wavelength which, when directed into the flowing blood within the blood conduit,

-71-

(A) is extinguished substantially the same amount by oxyhemoglobin and reduced hemoglobin in the flowing blood and

5 (B) is extinguished by the plasma in the flowing blood in a second manner substantially different from said first manner;

10 (iii) a first quantity of a radiation at a third radiation wavelength, which when directed into the flowing blood in the blood conduit,

(A) is extinguished by the competing biologic constituent in the flowing blood in a manner characteristic of the competing biologic constituent; and

15 (B) is extinguished by the constituents of the flowing blood other than the competing biologic constituent in a third manner, said third manner being substantially different from one of said first and second manners; and

20 (iv) a first quantity of a radiation at a fourth radiation wavelength, distinct from said first, second and third radiation wavelengths, and which, when directed into the flowing blood within the blood conduit,

25 (A) is extinguished substantially differently by oxyhemoglobin and by reduced oxyhemoglobin in the flowing blood, and which

30 (B) is not substantially extinguished by the plasma in the flowing blood;

(c) detecting the portion of said directed radiation which passes through both the blood conduit and the flowing blood therein with a radiation  
35 detection means situated within said conduit receiving

-72-

means, said detected portion of said directed radiation comprising:

- (i) a second quantity of a radiation at the first radiation wavelength,
- 5 (ii) a second quantity of a radiation at the second radiation wavelength,
- (iii) a second quantity of a radiation at the third radiation wavelength, and
- 10 (iv) a second quantity of a radiation at the fourth radiation wavelength;
- (d) operating on the second quantities of the radiations at the first and second radiation wavelengths to determine the hematocrit of the patient;
- 15 (e) determining the blood oxygen content value by the second quantities of the first, second, third, and fourth radiation wavelengths; and
- (f) displaying the blood oxygen content value.

99. A method for determining the hematocrit of the blood of a patient, the blood flowing in a pulsatile fashion in a body part of the patient or in an extracorporeal passageway in communication with the circulatory system of the patient so as to be subjectable to transcutaneous examination in the body part or to noninvasive examination in the extracorporeal passageway, the body part and the extracorporeal passageway defining a blood conduit and the method comprising the steps of:

- (a) placing the blood conduit within a blood conduit receiving means with the flowing blood in the blood conduit;
- 30 (b) directing radiation into the flowing blood within the blood conduit using a radiation generation means situated within the blood conduit receiving means, said radiation defining a directed radiation comprising:
- 35

-73-

(i) a first quantity of a radiation at a first radiation wavelength which, when directed into the flowing blood within the blood conduit,

5 (A) is extinguished substantially the same amount by oxyhemoglobin and reduced hemoglobin in the flowing blood and

(B) is extinguished by the plasma in the flowing blood in a first manner; and

10 (ii) a first quantity of radiation at a second radiation wavelength which, when directed into the flowing blood within the blood conduit,

(A) is extinguished substantially the same amount by oxyhemoglobin and reduced hemoglobin in the flowing blood and

15 (B) is extinguished by the plasma in the flowing blood in a second manner substantially different from said first manner;

20 (c) detecting the portion of said directed radiation which passes through both the blood conduit and the flowing blood therein with a radiation detection means situated within said conduit receiving means, said detected portion of said directed radiation comprising:

25 (i) a second quantity of a radiation at the first radiation wavelength, and

(ii) a second quantity of a radiation at the second radiation wavelength;

30 (d) operating on the second quantities of the radiations at the first and second radiation wavelengths to determine the hematocrit of the patient by determining the logarithmic intensity ratio of the second quantities of the first and the second radiation wavelengths.

-74-

100. A system for determining the hematocrit of the blood of a patient, the blood flowing in a pulsatile fashion in a body part of the patient or in an extracorporeal passageway in communication with the circulatory system of the patient so as to be subjectable to transcutaneous examination in the body part or to noninvasive examination in the extracorporeal passageway, the body part and the extracorporeal passageway defining a blood conduit and the system comprising:

(a) a blood conduit receiving means for receiving a blood conduit containing the flowing blood of the patient;

(b) emission means for directing radiation into the flowing blood within the blood conduit, said emission means being situated within said blood conduit receiving means, said radiation defining a directed radiation comprising;

(i) a first quantity of a radiation at a first radiation wavelength which, when directed into the flowing blood in the blood conduit,

(A) is extinguished substantially the same amount by oxyhemoglobin and reduced hemoglobin in the flowing blood and

(B) is extinguished by the plasma in the flowing blood in a first manner; and

(ii) a first quantity of a radiation at a second radiation wavelength which, when directed into the blood flowing within the blood conduit,

(A) is extinguished substantially the same amount by oxyhemoglobin and reduced hemoglobin in the flowing blood and

(B) is extinguished by the plasma in the flowing blood in a second manner substantially different from said first manner;

-75-

(c) detection means for detecting the portion of said directed radiation which passes through both the blood conduit and the flowing blood therein, said detection means being situated within said blood conduit receiving means, said detected portion of said directed radiation comprising:

(i) a second quantity of a radiation at the first radiation wavelength, and

(ii) a second quantity of a radiation at the second radiation wavelength;

(d) calculation means for determining the hematocrit of the patient by operating on the second quantities of the first and second wavelengths, wherein the calculation means includes means for determining the logarithmic intensity ratio of the second quantities of the first and second radiation wavelengths.

## AMENDED CLAIMS

[received by the International Bureau  
on 09 August 1994 (09.08.94);  
original claims 2-5, 16, 90-94 and 96 amended;  
remaining claims unchanged (8 pages)]

the maximum and the minimum intensity of a pulsatile  
component of the first radiation wavelength;

5 (c) determining the ratio between the first  
radiation wavelength pulsatile value and the intensity  
of the total first radiation wavelength over a period  
of time; and

(d) determining a first mean ratio value over a  
period of time of the ratio between the first  
radiation wavelength pulsatile component and the  
10 average intensity of the first radiation wavelength.

3. A method as defined in Claim 2, wherein the step  
of detecting the second quantity of the second radiation  
wavelength comprises the steps of:

15 (a) determining the intensity of the total  
second radiation wavelength;

(b) determining a second radiation wavelength  
pulsatile value representing the difference between  
the maximum and the minimum intensity of a pulsatile  
component of the second radiation wavelength;

20 (c) determining the ratio between the second  
radiation wavelength pulsatile value and the intensity  
of the total second radiation wavelength over a period  
of time;

(d) determining a second mean ratio value over  
25 a period of time of the ratio between the second  
radiation wavelength pulsatile component and the  
average intensity of the second radiation wavelength;  
and

(e) wherein the step of operating to determine  
30 the desired biologic constituent concentration of the  
patient by operating exclusively on the second  
quantities of the first and second radiation  
wavelengths comprises the step of determining the  
desired biologic constituent concentration of the

- 77 -

patient by the ratio between the first mean ratio value and the second mean ratio value.

4. A method as defined in Claim 1, wherein the step of detecting the second quantity of the first radiation wavelength comprises the steps of:

(a) determining the intensity of the total first radiation wavelength;

(b) determining a first radiation wavelength pulsatile value representing the true time derivative of a pulsatile component of the first radiation wavelength;

(c) determining the ratio between the first radiation wavelength pulsatile value and the intensity of the total first radiation wavelength over a period of time; and

(d) determining a first mean ratio value over a period of time of the ratio between the first radiation wavelength pulsatile component and the average intensity of the first radiation wavelength.

5. A method as defined in Claim 4, wherein the step of detecting the second quantity of the second radiation wavelength comprises the steps of:

(a) determining the intensity of the total second radiation wavelength;

(b) determining a second radiation wavelength pulsatile value representing the true time derivative of a pulsatile component of the second radiation wavelength;

(c) determining the ratio between the second radiation wavelength pulsatile value and the intensity of the total second radiation wavelength over a period of time;

(d) determining a second mean ratio value over a period of time of the ratio between the second radiation wavelength pulsatile component and the

- 78 -

times smaller than said first extinguishment value for the plasma in the flowing blood.

12. A method as defined in Claim 1, wherein the first radiation wavelength is in the range from about 780  
5 nanometers to about 850 nanometers.

13. A method as defined in Claim 1, wherein the first radiation wavelength is in the range from about 520 nanometers to about 600 nanometers.

14. A method as defined in Claim 1, wherein the third  
10 extinguishment value is substantially the same amount for oxyhemoglobin and for reduced hemoglobin in the flowing blood and the fourth extinguishment value is approximately the same as said third extinguishment value for the plasma in the flowing blood.

15. A method as defined in Claim 1, wherein the  
15 second radiation wavelength is in the range from about 1200 nanometers to about 1600 nanometers.

16. A method as defined in Claim 1, wherein the  
20 flowing blood includes a competing biologic constituent relative to the hemoglobin in the blood, and wherein:

(a) said directed radiation in said step of directing radiation into the flowing blood within the blood conduit further comprises a first quantity of a radiation at a third radiation wavelength, distinct  
25 from said first and second radiation wavelengths, and which, when directed into the flowing blood in the blood conduit,

(i) has a fifth extinguishment value which varies with the competing biologic constituent concentration in the flowing blood, said fifth extinguishment value being at least five times greater than said second extinguishment value; and  
30

(ii) has a sixth extinguishment value which varies with the concentration of components other  
35

- 79 -

minimum extinguishment of a pulsatile component of the first radiation wavelength;

(C) determining the ratio between the first radiation wavelength pulsatile value and the extinguishment of the total first radiation wavelength over a period of time; and

(D) determining a first mean ratio value over a period of time of the ratio between the first radiation wavelength pulsatile component and the average extinguishment of the first radiation wavelength, and

(ii) a second quantity of a radiation at the second radiation wavelength;

(d) operating on the second quantities of the radiations at the first and second radiation wavelengths to determine the hematocrit of the patient.

91. A method as defined in Claim 90, wherein the step of detecting the second quantity of the second radiation wavelength comprises the steps of:

(a) determining the extinguishment of the total second radiation wavelength;

(b) determining a second radiation wavelength pulsatile value representing the difference between the maximum and the minimum extinguishment of a pulsatile component of the second radiation wavelength;

(c) determining the ratio between the second radiation wavelength pulsatile value and the extinguishment of the total second radiation wavelength over a period of time;

- 80 -

(B) is extinguished by the plasma in the flowing blood in a first manner; and

(ii) a first quantity of radiation at a second radiation wavelength which, when directed into the flowing blood within the blood conduit,

(A) is extinguished substantially the same amount by oxyhemoglobin and reduced hemoglobin in the flowing blood and

(B) is extinguished by the plasma in the flowing blood in a second manner substantially different from said first manner;

(c) detecting the portion of said directed radiation which passes through both the blood conduit and the flowing blood therein with a radiation detection means situated within said conduit receiving means, said detected portion of said directed radiation comprising:

(i) a second quantity of a radiation at the first radiation wavelength, and

(ii) a second quantity of a radiation at the second radiation wavelength being detected by steps comprising:

(A) determining the extinguishment of the total first radiation wavelength;

(B) determining a first radiation wavelength pulsatile value representing the true time derivative of a pulsatile component of the first radiation wavelength;

(C) determining the ratio between the first radiation wavelength pulsatile value and the extinguishment of the total first radiation wavelength over a period of time; and

- 81 -

5 (D) determining a first mean ratio value over a period of time of the ratio between the first radiation wavelength pulsatile component and the average extinguishment of the first radiation wavelength;

10 (d) operating on the second quantities of the radiations at the first and second radiation wavelengths to determine the hematocrit of the patient.

93. A method as defined in Claim 92, wherein the step of detecting the second quantity of the second radiation wavelength comprises the steps of:

15 (a) determining the extinguishment of the total second radiation wavelength;

(b) determining a second radiation wavelength pulsatile value representing the true time derivative of a pulsatile component of the second radiation wavelength;

20 (c) determining the ratio between the second radiation wavelength pulsatile value and the extinguishment of the total second radiation wavelength over a period of time;

25 (d) determining a second mean ratio value over a period of time of the ratio between the second radiation wavelength pulsatile component and the average extinguishment of the second radiation wavelength; and

30 (e) wherein the step of determining the hematocrit of the patient by operating on the second quantities of the first and second radiation wavelengths comprises the step of determining the hematocrit of the patient by the ratio between the first mean ratio value and the second mean ratio value.

35

- 82 -

substantially different from said first manner; and

(iii) a first quantity of a radiation at a third radiation wavelength, which when directed into the flowing blood in the blood conduit,

(A) is extinguished by the competing biologic constituent in the flowing blood in a manner characteristic of the competing biologic constituent; and

(B) is extinguished by the constituents of the flowing blood other than the competing biologic constituent in a third manner, said third manner being substantially different from one of said first and second manners;

(c) detecting the portion of said directed radiation which passes through both the blood conduit and the flowing blood therein with a radiation detection means situated within said conduit receiving means, said detected portion of said directed radiation comprising:

(i) a second quantity of a radiation at the first radiation wavelength,

(ii) a second quantity of a radiation at the second radiation wavelength, and

(iii) a second quantity of a radiation at the third radiation wavelength being detected by steps comprising:

(A) determining the extinguishment of the total third radiation wavelength;

(B) determining a third radiation wavelength pulsatile value representing the difference between the maximum and the minimum extinguishment of a pulsatile component of the third radiation wavelength;

- 83 -

(c) detecting the portion of said directed radiation which passes through both the blood conduit and the flowing blood therein with a radiation detection means situated within said conduit receiving means, said detected portion of said directed radiation comprising:

(i) a second quantity of a radiation at the first radiation wavelength,

(ii) a second quantity of a radiation at the second radiation wavelength, and

(iii) a second quantity of a radiation at the third radiation wavelength being detected by steps comprising:

(A) determining the extinguishment of the total third radiation wavelength;

(B) determining a third radiation wavelength pulsatile value representing the true time derivative of a pulsatile component of the third radiation wavelength;

(C) determining the ratio between the third radiation wavelength pulsatile value and the extinguishment of the total third radiation wavelength over a period of time;

(D) determining a third mean ratio value over a period of time of the ratio between the third radiation wavelength pulsatile component and the average extinguishment of the third radiation wavelength;

(d) operating on the second quantities of the radiations at the first and second and third radiation wavelengths to determine the corrected hematocrit of the patient by determining the hematocrit of the patient by the combination of the first, second, and third mean ratio values.

**STATEMENT UNDER ARTICLE 19**

Please amend the claims in the above-identified application by cancelling sheets 28, 29, 31, 61, 63, 64, 66, 69 and 76 of this application which contain sections of the claims and the abstract. Please substitute therefore, sheets 28, 29, 31, 61, 63, 64, 66, 69 and 76, attached hereto, which contain amendments to the claims and the abstract to be entered in this application.

The amendments to the claims submitted herewith place this application into conformity with the amendments entered into the corresponding U.S. application which has been allowed, and is awaiting issuance.




FIG. 1






FIG. 1A



**FIG. 18**



3/27




FIG. 3

4/27




FIG. 4

5/27




FIG. 5A

6/27




FIG. 5B

7/27




FIG. 5C

8/27




FIG. 5D

9/27




FIG. 6




FIG. 6A

10/27




FIG. 7

11/27




FIG. 8A

12/27






FIG. 8B

13/27



## EXPANSION CONNECTOR



EPROM SIZE	OP1	OP2	OP3	OP4
27C32	X	L	X	X
27C64	L	X	L	L
27C128	L	R	L	L
27C256	L	R	L	R
27C512	L	R	R	R
27C010	X	R	R	R
27C020	R	R	R	R

FIG. 8C



15/27






FIG. 9B






FIG. 9D

18/27




FIG. 10A

19/27




FIG. 10B

20/27





FIG. 10C




FIG. 11

22/27




FIG. 12

23/27




FIG. 13A

24/27




FIG. 13B

25/27




FIG. 14A

26/27




FIG. 14B

27/27




FIG. 15




FIG. 16

## INTERNATIONAL SEARCH REPORT

International application No.  
T/US93/03427

## A. CLASSIFICATION OF SUBJECT MATTER

IPC(5) : A61B 05/00

US CL : 128/633

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 128/633,634,664,665,666 356/41

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched  
none

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)  
none

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	US,A, 4,925,299 (Meisberger et al.) 15 May 1990. See entire document.	1 3 , 2 2 , 2 8 , 35,49,55, 87
X -- Y	US,A, 5,066,859 (Karkar et al.) 19 November 1991. See entire document.	1,23,24,26 27,38,46- 48,60-63 ----- 8,9,13,16- 22,25,28- 38,44,45, 49,50-59, 64-67,76, 77,83-90
A	US,A, 5,101,825 (Gravenstein et al.) 07 April, 1992. See entire document.	1-100

☒ Further documents are listed in the continuation of Box C. ☐ See patent family annex.

* Special categories of cited documents:	T	later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
"A" document defining the general state of the art which is not considered to be part of particular relevance	"X"	document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
"E" earlier documents published on or after the international filing date	"Y"	document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	"A"	document member of the same patent family
"O" document referring to an oral disclosure, use, exhibition or other means		
"P" document published prior to the international filing date but later than the priority date claimed		

Date of the actual completion of the international search

29 July 1993

Date of mailing of the international search report

07 SEP 1993

Name and mailing address of the ISA/US  
Commissioner of Patents and Trademarks  
Box PCT  
Washington, D.C. 20231

Authorized officer  
Robert L. Nasser Jr.

Facsimile No. NOT APPLICABLE

Telephone No. (703) 308-3251

## INTERNATIONAL SEARCH REPORT

International application No.  
PCT/US93/03427

## C (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X --- Y	US,A, 4,805,623 (Jobis) 21 February 1993. See entire document.	1,15 ----- 19-22,29, 32-39,50- 59,64-67, 82-89
X ----- Y	US, A, 3,638,604 (Shaw) 01 February 1972. See entire document.	1,6, 10-12, 14, 68, 74,75, 78, 79, and 81  ----- 7-9, 16-22, 30- 38, 50-59, 64-67, 73, 76,77, 80, 82-90
Y	US, A, 5,054,487 (Clarke) 08 October 1991. See entire document.	7, 25, 44, 73

**This Page is Inserted by IFW Indexing and Scanning  
Operations and is not part of the Official Record**

**BEST AVAILABLE IMAGES**

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☐ BLACK BORDERS
- ☐ IMAGE CUT OFF AT TOP, BOTTOM OR SIDES
- ☐ FADED TEXT OR DRAWING
- ☒ BLURRED OR ILLEGIBLE TEXT OR DRAWING
- ☐ SKEWED/SLANTED IMAGES
- ☐ COLOR OR BLACK AND WHITE PHOTOGRAPHS
- ☐ GRAY SCALE DOCUMENTS
- ☐ LINES OR MARKS ON ORIGINAL DOCUMENT
- ☐ REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY
- ☐ OTHER: \_\_\_\_\_

**IMAGES ARE BEST AVAILABLE COPY.**

**As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.**